Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

Sandra Ortiz-Cuaran1*, Jebrane Bouaoud1,2,3, Andy Karabajakian1,2, Jérôme Fayette1,2 and Pierre Saintigny1,2*

1 Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France, 2 Department of Medical Oncology, Centre Léon Bérard, Lyon, France, 3 Department of Maxillofacial Surgery and Stomatology, Pitié-Salpêtrière University Hospital, Pierre et Marie Curie University, Sorbonne University, Paris, France

Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer worldwide. More than half of HNSCC patients experience locoregional or distant relapse to treatment despite aggressive multimodal therapeutic approaches that include surgical resection, radiation therapy, and adjuvant chemotherapy. Before the arrival of immunotherapy, systemic chemotherapy was previously employed as the standard first-line protocol with an association of cisplatin or carboplatin plus 5-fluorouracil plus cetuximab (anti-EFGR antibody). Unfortunately, acquisition of therapy resistance is common in patients with HNSCC and often results in local and distant failure. Despite our better understanding of HNSCC biology, no other molecular-targeted agent has been approved for HNSCC. In this review, we outline the mechanisms of resistance to the therapeutic strategies currently used in HNSCC, discuss combination treatment strategies to overcome them, and summarize the therapeutic regimens that are presently being evaluated in early- and late-phase clinical trials.

Keywords: head and neck squamous-cell carcinoma, resistance, chemotherapy, cetuximab, immunotherapy, targeted therapy

INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer worldwide, responsible for more than 700,000 cases worldwide per year and around 350,000 deaths, making it a particularly fatal disease (1).

Squamous cell cancers of the oral cavity, the pharynx, and the larynx (the most frequent) are linked to smoking and alcohol consumption, and squamous cell carcinomas of the oropharynx are most
commonly associated with human papilloma virus (HPV) infection, especially for young or nonsmoker patients. The incidence of the latter is rising, mostly among men (2). Cigarette- or alcohol-related and HPV-induced cancers are described by the 2017 World Health Organization (WHO) as two different clinical entities with different oncogenic pathways and prognostics (3). Other anatomical localizations of head and neck cancers include the sinuses and nasal fossae, which are rare and rather linked to professional and environmental exposures.

More than half of HNSCC patients experience locoregional or distant relapse despite aggressive multimodal therapeutic approaches that include surgical resection (often with neck dissection), radiation therapy (exclusive or postoperative), and adjuvant chemotherapy given as a radiosensitizer (4). After relapse, treatment options are often limited due to a high risk of complications (e.g., fistulas, dysphagia, spinal cord myelopathy) if surgery or reirradiation are attempted. If a salvage surgery (with R0 resection) or reirradiation is indeed deemed unfeasible, then systemic treatment options (detailed in this review) are proposed. Before the arrival of immunotherapy, systemic chemotherapy was employed as the standard first-line protocol with an association of cisplatin or carboplatin and 5-fluorouracil plus cetuximab (anti-EFGR antibody), known as the EXTREME protocol, which confers a dismal median overall survival (OS) of around 10 months (5).

In this review, we outline the mechanisms of resistance to the therapeutic strategies currently used in HNSCC, discuss combination treatment strategies to overcome them, and summarize the therapeutic regimens that are presently being evaluated in early- and late-phase clinical trials.

MECHANISMS OF RESISTANCE TO CHEMOTHERAPY

Chemotherapy is currently used as the therapeutic option for advanced HNSCC tumors (T3 or T4), concurrent to radiation, if surgical resection is deferred in the primary setting. For recurrent or metastatic disease and for cases in which first-line treatment with immunotherapy is not feasible, first-line systemic chemotherapy is advised with a protocol that includes cisplatin or carboplatin plus 5-fluorouracil and cetuximab (5, 6). Unfortunately, acquisition of chemotherapy resistance is common in patients with HNSCC and often results in local and distant failure.

Cancer Stem Cells and EMT

Epithelial-to-mesenchymal transition (EMT) is a reversible embryonic transdifferentiation program that allows partial or complete transition from an epithelial to a mesenchymal state (7). Although EMT was initially considered to be involved in invasion and metastatic spread, its key role in the initiation and development of primary tumors as well as in resistance to therapy is also demonstrated (8).

Nasopharyngeal carcinoma (NPC) is a highly invasive head–neck cancer derived from the nasopharyngeal epithelium. Preclinical studies in NPC cells demonstrate that resistance to radiotherapy and adjuvant cisplatin (DDP) chemotherapy is associated with morphological and molecular marker changes consistent with EMT. Mechanistically, depletion of NEDD4 in resistant cells leads to a partial reversion of the EMT phenotype, suggesting that NEDD4 promotes EMT features and chemoresistance of NPC in vitro (9). In a subsequent study, analysis of parental HNE1 and cisplatin-resistant HNE1/DDP NPC cells reveals that the upregulation of miR-139-5p expression inhibits proliferation, invasion, migration, and EMT. In these cells, miR-139-5p expression levels positively correlate with DDP-induced apoptosis, suggesting that miR-139-5p is associated with DDP resistance in human NPC by modulating the EMT (10).

More recently, it was demonstrated that epithelial mesenchymal crosstalk (EMC), which constitutes the interaction of the tumor stroma and associated fibroblasts with epithelial cancer cells, induces a hybrid epithelial–mesenchymal phenotype in HNSCC cells that is associated with chemotherapy resistance, via IL-6/STAT3 pathway activation (11). Interestingly, transcriptome analyses of HNSCC cell lines reveals that STAT1 and STAT3 activation enable aldo-keto reductase family 1 member C1 (AKR1C1)-induced resistance to cisplatin, which can be overcome by ruxolitinib treatment (12).

Cisplatin-resistant oral squamous cell carcinoma (OSCC) cells exhibit an enriched putative cancer stem–like signature with increased expression of CD44 and Oct-4 and enhanced sphere-forming ability, coupled with the acquisition of an EMT phenotype. This study also reveals that, irrespective of drug treatment, cell migration is significantly increased in cisplatin-resistant cell lines compared with drug-sensitive cells. In line with these observations, bioinformatic analysis of miRNA–mRNA networks in cisplatin-resistant OSCC cells reveals the upregulation of ATP-binding cassette (ABC) transporter genes, genes associated with inhibition of apoptosis (e.g., BIRC family) and cancer stem cell (CSC) marker CD44 (13).

A subpopulation of CSCs characterized by high levels of CD44v3 and aldehyde dehydrogenase-1 (ALDH1) expression has been identified in HNSCC-derived HSC-3 cells and HNSCC patient samples. In HSC-3 cells, it is shown that hyaluronan (HA) stimulates the interaction of CD44v3 with Oct-4–Sox2–Nanog, which results in the nuclear translocation of these three CSC transcription factors. Notably, it is demonstrated that Oct-4–Sox2–Nanog–dependent activation of miR-302 promotes the
upregulation of the survival proteins cIAP-1, cIAP-2, and XIAP, leading to self-renewal and cisplatin resistance. In this context, transfection with an anti-miR-302 inhibitor is shown to downregulate the expression of these survival proteins and to abrogate the HA-CD44v3-mediated sphere formation and chemoresistance (14). It is noteworthy that the histone methyltransferase DOT1L is also upregulated by HA in CSCs isolated from HSC-3 cells and results in the overexpression of RhoGTPases and survival proteins involved in cell invasion and cisplatin resistance (15).

Inhibition of the aldehyde dehydrogenase 1 family member A1 (ALDH1A1) in cisplatin-resistant HNSCC cells results in downregulation of CSC markers that are diminished in migratory, self-renewal, and tumorigenic potential and resensitizes HNSCC cells to cisplatin. These observations are further validated in four ex vivo explants from HNSCC patients in which combined treatment of cisplatin and NCT-501, a theophylline-based inhibitor of ALDH1A1, results in a significant decrease in proliferating cells as compared with monotherapy (16). In a subsequent study, gene set enrichment analysis identified enhanced FGF2 expression in cisplatin-resistant ALDHhigh/CD44high HNSCC cells. Pharmacological inhibition of FGF signaling using BGJ398 preferentially targeted the ALDHhigh/CD44high subpopulation, suggesting that FGF signaling plays a key role in in vitro stemness and in cisplatin resistance in HNSCC cells (17).

Of note, preclinical studies show that long noncoding RNA FOXD2-AS1 regulates therapeutic resistance in laryngeal squamous cell carcinoma (LSCC) by acting as an upstream activator of STAT3, which is essential to maintain cancer stemness. In LSCC patients, FOXD2-AS1 expression was predictive of poor prognosis in chemotherapy-resistant patients (18).

Overall, these studies show that the acquisition of CSC properties and the transition to a mesenchymal phenotype mediate chemotherapy resistance of HNSCC.

DNA Damage
Cisplatin triggers the formation of phosphorylated histone H2AX (γ H2AX)-positive foci at the site of DNA damage (19), dependent on ATR and via the activation of downstream CHEK1/2 (20). In HNSCC, as well as in other cancer types, altered DNA damage response signaling has been associated with resistance to chemotherapies (21).

Indeed, functional depletion of DDR effectors WDHD1, DSCC1, CSNK2B, POLR2I, and RAD54L in HNSCC cells treated with cisplatin results in decreased ATR serine/threonine kinase (ATR) phosphorylation and reduces cisplatin-induced of γ H2AX foci, suggesting that impaired DDR signaling is a driving mechanism of cisplatin resistance in HNSCC in vitro (21). Moreover, gene expression analysis of pretreatment biopsy specimens from 64 HNSCC patients treated with 5-FU/cisplatin identified that ERCC1 expression is a significant predictor of response to chemotherapy, further indicating that DNA repair is a pivotal mechanism implicated in response to chemotherapy in HNSCC (22).

At present, clinical trials are evaluating the efficacy of targeting DNA damage response in HNSCC. ATR acts as a DNA damage sensor, activating cell cycle checkpoint signaling upon DNA stress. Pharmacological inhibition of ATR using M6620 is currently being tested in combination with cisplatin and radiation therapy in the setting of locally advanced HNSCC (NCT02567422). Similarly, a modular, phase-I/II, open-label trial is ongoing to evaluate the efficacy of ceralasertib (AZD6738, ATR inhibitor) in combination with carboplatin (NCT02264678).

Along the same lines, because PARP is involved in DNA repair, inhibition of PARP may enhance the damaging effects of chemotherapy on tumor DNA. A phase-I/II study recently reported the safety and efficacy of veliparib, a PARP inhibitor, in combination with carboplatin-paclitaxel chemotherapy in patients with locoregionally advanced HNSCC (23). The WEE1 tyrosine kinase maintains genomic stability and regulates G2–M transition, particularly in p53-deficient tumors, protecting cells against replication stress and subsequent cell death. A phase-I clinical trial evaluating the triplet combination of AZD1775 (WEE1 inhibitor), cisplatin and docetaxel reported satisfactory results in terms of safety and tolerability as well as promising antitumor efficacy in patients with stage-III/IVB HNSCC (i.e., partial response in 5 patients and stable disease in 4 patients) (24).

Epigenetic Modifications
Resistance to cisplatin-based chemotherapy can be also modulated by epigenetic alterations. Indeed, hypermethylation of the promoter CpG islands of the neurofilament light polypeptide (NEFL) gene is associated with resistance to cisplatin-based chemotherapy in HNSCC cell lines. Functional analyses showed that NEFL interacts with tuberous sclerosis complex 1 (TSC1) at the protein level. Because TSC1 is a negative regulator of the mTOR pathway, it is suggested that NEFL downregulation results in functional activation of the mTOR pathway and, thus, cisplatin resistance. Interestingly, in this study, analysis of more than 50 HNSCC patient samples evidenced that NEFL promoter hypermethylation predicted diminished OS and disease-free survival in patients treated with cisplatin-based chemotherapy (25). A recent clinical trial evaluated the impact of mTOR pathway inhibition in HNSCC patients in the neoadjuvant setting. This study reports that rapamycin treatment was well tolerated, reduced mTOR signaling (i.e., phosphorylation of S6, AKT, and e4EBP) and tumor growth, and resulted in significant clinical responses in 4/16 of patients (1 complete response, 3 partial responses, and 12 stable disease) (26).

Histone modifiers are essential for chromatin dynamics and gene expression, and their dysregulated function may alter gene regulation in favor of oncogenic growth. Elevated expression of p21-activated kinase 2 (PAK2), a binding partner of the Rho GTPases that are implicated in chromatin remodeling, cell proliferation, and apoptosis, is correlated with chemoresistance and is associated with the poor clinical outcome of HNSCC patients. Mechanistically, PAK2 upregulates c-Myc expression, which, in turn, transcriptionally activates and induces pyruvate kinase M2 (PKM2) expression, resulting in reduced aerobic glycolysis, proliferation, and chemotherapeutic resistance of HNSCC cells (27).
Small noncoding RNAs are also key effectors of transcriptional gene silencing in HNSCC. Analysis of global miRNA expression in CD44-expressing HNSCC cells reveals that miR-629-3p expression promotes cell migration and inhibits apoptotic cell death upon cisplatin treatment. Of note, miR-629-3p-transfected cells display a significant enrichment of gene sets associated with drug metabolism and EMT. Interestingly, the role of miR-629-3p in conferring resistance to cisplatin was also observed in a xenograft model, and the expression of miR-629-3p was associated with decreased survival in HNSCC patients, potentially suggesting a physio-pathological role of miR-629-3p in resistance to cisplatin in HNSCC (28).

Enhanced expression of miR-96-5p is shown to promote cell migration but not cell proliferation, in p53-mutant HNSCC cell lines and to drive resistance to radiotherapy and cisplatin-based chemotherapy in vitro (29). Of note, this study identified PTEN, a negative regulator of the intracellular levels of phosphatidylinositol-3,4,5-trisphosphate as a direct target of miR-96-5p through the binding to its cognate site on the 3’UTR of PTEN. Interestingly, functional experiments performed in vitro shows that PTEN depletion recapitulates the biological effects of miR-96-5p overexpression in HNSCC cells as they were less prone to cisplatin-induced cell killing (29).

At present, a noninterventional clinical trial (NCT03953443) is evaluating the impact of expression and epigenetic silencing of microRNAs for predicting therapeutic response and prognosis of HPV-negative HNSCC.

Further knowledge on the epigenetic alterations that promote HNSCC chemoresistance can open the possibility for the development of therapeutic strategies that can be used as an adjuvant therapy associated with conventional chemotherapeutic drugs to enhance treatment effectiveness.

**Evasion of apoptosis**

The adaptive response to chemotherapy in HNSCC is modulated by changes in the expression of pro- or anti-apoptotic proteins and include defects in cellular responses caused by mutations of tumor suppressor gene TP53 (30, 31).

Survivin (BIRC5), a member of the inhibitor of apoptosis (IAP) gene family, is shown to be significantly upregulated in HNSCC primary tumors and cell lines and to be particularly highly expressed in HPV-negative patients who generally respond poorly to cisplatin treatment (32). Immunohistochemical and mutational analyses on HNSCC biopsies from patients displaying high levels of nuclear survivin (BIRC5) identified the presence of the somatic mutation c.278T>C (p.Phe93Ser). Functional characterization of this mutant by ectopic expression and microinjection experiments revealed that it attenuates the cytoprotective activity of survivin against chemoradiation-induced apoptosis. Therefore, genetic inactivation of survivin may promote an increased therapy response in cancer patients (33).

Interestingly, pharmacological inhibition of survivin using the small molecule YM155, either as a single agent or in combination with cisplatin, evidenced a significant dose-dependent decrease in cell proliferation and the reversion of cisplatin resistance in in vitro and in vivo models of HNSCC. Mechanistically, YM155 induced a rapid reduction of survivin in the cytoplasm, which is key for its antiapoptotic function (32). Thus, survivin inhibition might potentially be a novel strategy to enhance the effectiveness of chemotherapy in HNSCC.

The x-linked inhibitor of apoptosis (XIAP) is an E3 ubiquitin protein ligase that functions through binding to tumor necrosis factor receptor–associated factors TRAF1 and TRAF2 to inhibit apoptosis. Analysis of XIAP expression in tumor samples from 60 patients with advanced HNSCC, before and after chemotherapy, evidenced that XIAP is a predictor of cisplatin response and prognosis for patients with advanced HNSCC. Interestingly, preclinical experiments show that inhibiting XIAP expression with siRNA in XIAP-high HNSCC cells markedly increased their sensitivity to cisplatin treatment (30). Of note, the dual cIAP/XIAP antagonist ASTX660 significantly delays growth of both HPV- and HPV+ human tumor xenografts in combination with radiotherapy.

Resistance to the activity of TNF-related apoptosis inducing ligand (TRAIL), an effector of tumor cell–specific apoptosis, is associated with HPV positivity in HNSCC in vitro. HPV-positive HNSCC cell lines were sensitized to TRAIL-induced cell death by bortezomib-mediated proteasome inhibition via the activation of caspases 8, 9, and 3; increased membrane expression of TRAIL-R2; and G2/M arrest. Of note, XIAP depletion also augmented HPV-positive HNSCC cell death in response to TRAIL alone and in combination with bortezomib (34).

**Tumor Microenvironment (TME)**

HNSCC tumors are commonly associated with hypoxia, which is characterized by an acute or chronic decline in oxygen tension.

Activin receptor-like kinase (ALK)-1 represents a promising target for antiangiogenic therapy in solid tumors. activin receptor-like kinase-1 ligand trap (ALK1-Fc) is a chimeric protein consisting of the ALK1 extracellular domain fused to the Fc-part of an antibody. ALK1-Fc prevents the binding of BMP9 and BMP10 to the endothelial ALK1 receptor, which results in decreasing angiogenic responses (35). Therapeutic combination of ALK1-Fc with cisplatin is shown to inhibit tumor growth in HNSCC in vivo models more efficiently than chemotherapy alone. Treatment of mice with ALK1-Fc strongly decreased the microvascular density of tumors, increased the pericyte coverage of the remaining tumor vessels, and decreased the hypoxia within the tumor (36). Interestingly, results of an early-phase clinical trial show that the ALK1-Fc displayed promising antitumor activity in HNSCC patients with advanced refractory cancer (35).

Signaling via the SDF-1/CXCR4 axis, a chemokine-receptor pathway, is involved in cancer progression due to its roles in modulation of dendritic cells, enhanced matrix metalloproteinase activity, and the induction of TNF-alpha production and angiogenesis. Analysis of the expression of SDF-1 and CXCR4 in a cohort of 221 patients with locally advanced HNSCC evidenced that SDF-1 is associated with resistance to adjuvant radiotherapy concurrent with cisplatin-based chemotherapy (37). In this study, neither SDF-1 nor CXCR4 expression were associated with distant metastasis or with OS. The functional basis of these observations as well as the potential role of SDF-1/CXCR4 as a therapeutic
target to overcome treatment resistance in HNSCC remains to be determined.

In preclinical models of OSCC, combination therapy of cisplatin and inhibitors of VEGFR (i.e., pazopanib and nintedanib) was more potent than treatment with chemotherapy alone (38). The efficacy and toxicity of docetaxel with or without vandetanib, an inhibitor of VEGFR, RET, and EGFR, was investigated in patients with advanced recurrent or metastatic HNSCC. This trial shows only a minor trend toward improved PFS for the combination arm (39).

Of note, a current clinical trial is ongoing to evaluate the combination of atezolizumab (humanized IgG1 antibody against PD-L1) and bevacizumab (monoclonal antibody developed against VEGF) in patients with recurrent or metastatic HNSCC (ATHENA, NCT03818061).

The TME also constitutes a reservoir of cancer-associated fibroblasts (CAFs) which, in a close crosstalk with tumor cells, enhance the production of growth factors, cytokines, chemokines, and inflammatory mediators to promote tumor growth (40). CAFs are observed in both primary and metastatic HNSCC, and oral CAFs are reported to acquire rapid growth and increased proliferation and viability compared with normal oral fibroblasts (40). CAF-secreted paracrine factors increase HNSCC migration, invasion, and proliferation in vitro and promote tumor growth and metastases in vivo (i.e., orthotopic floor-of-the-mouth tumor model) (41).

CAFs are also known to mediate resistance to anticancer drugs in HNSCC. In HNSCC cell lines, culture with conditioned medium from a tumor cell/CAF coculture induced cisplatin resistance and increased their colony-formation capacity (11). Interestingly, exosomal miR-196a released by CAFs targets CDKN1B and INGS and, thus, confers cisplatin resistance in vitro (42). Interestingly, in this context, high levels of plasma exosomal miR-196a are clinically correlated with poor OS and chemoresistance in HNSCC patients. In line with these observations, it is demonstrated that, in OSCC patients, CAFs secrete increased levels of midkine (a heparin-binding growth factor that promotes carcinogenesis and chemoresistance) and abrogated cisplatin-induced cell death (43). Finally, analysis of tumor specimens obtained from 60 OSCC patients who underwent surgery following 5-fluorouracil-based chemoradiotherapy revealed that higher numbers of CAFs and tumor-associated macrophages (TAMs) were significantly correlated with a poor prognosis, suggesting their potential as biomarkers for predicting the clinical response to 5-FU-based chemoradiotherapy (44).

Understanding how CAFs contribute to drug resistance, proliferation, invasion, and metastasis might open up new strategies for the diagnosis, prognosis, and therapy of HNSCC.

**MECHANISMS OF RESISTANCE TO CETUXIMAB**

Initially described in 1962 by Cohen (45, 46), the epidermal growth factor receptor (EGFR) is a transmembrane receptor with tyrosine kinase activity (47). Several ligands bind specifically EGFR (e.g., epidermal growth factor [EGF], tumor growth factor-alpha [TGF-alpha], and amphiregulin), and others (betacellulin, heparin-binding growth factor [HB-EGF], and epiplacatin) bind to both EGFR and ErbB4 (48–50). Ligand binding induces the homo- or hetero-dimerization of EGFR, which is followed by the activation of downstream signaling, mainly via the RAS–RAF–MEK–ERK, the PI3K–AKT–mTOR, and the JAK–STAT cascades (51). These pathways are involved in the carcinogenesis and invasiveness of many cancer types (52).

Because EGFR is overexpressed in 80%–90% of HNSCC cases, tumors are often addicted to EGFR signaling for sustained survival and proliferation, and this overexpression is correlated with poor prognosis and treatment outcomes (53–55), therapies targeting EGFR have been widely evaluated for HNSCC (56–58): first, intravenous anti-EGFR antibodies that bind to the extracellular domain of the receptor causing its internalization to prevent its activation by other ligand–receptor interactions (59) while favoring antibody-dependent cell-mediated cytotoxicity (i.e., ADCC, which refers to the linking to innate and adaptive antitumor immune responses via NK cells and antigen-presenting cells that lead to EGFR-specific T cells) (60–63) and ii-oral EGFR tyrosine kinase inhibitors (TKI) binding to the intracellular domain of EGFR inhibiting its autophosphorylation (blocking of the ATP binding to the intracellular tyrosine kinase domain of EGFR) and downstream signaling (56, 64, 65).

Cetuximab (CTX), a monoclonal antibody targeting the EGFR extracellular domain, is to date the only targeted therapy that has demonstrated benefits in OS in combination with both radiotherapy for patients with locally advanced HNSCC (66) and chemotherapy (platinum, 5-FU, and CTX) as the first-line treatment of patients with recurrent and/or metastatic HNSCC (5, 67). Of note, CTX has never proven to be effective postoperatively (56, 58, 68).

Despite our better understanding of HNSCC biology (51, 69–71), no other molecular-targeted agent has been approved for HNSCC (12). Furthermore, CTX has shown limited efficacy in HNSCC with an overall response rate of 10%–20%, contrasting with the high rates of EGFR overexpression (51, 72). This underlines the existence of resistance mechanisms, remaining unresolved, but for which several hypotheses have been proposed (48, 56, 64, 67, 73–81) (4, 12, 21, 24, 29–37). The different type of resistance mechanisms to CTX could be defined as follows: alterations of the EGFR-ligand binding, alterations of the EGFR downstream signaling effectors, parallel/bypass pathway activation, alterations of proteins involved in classic cancer pathways, EMT, epigenetic alterations and establishment of an immunosuppressive TME (Figure 1). In this review and for each CTX resistance mechanism, we report preclinical (based on HNSCC cell lines/xenograft) and clinical evidence of CTX resistance as well as ongoing clinical trials of CTX-based combined therapies to overcome CTX resistance (Table 1).

**Alterations in EGFR and Its ligands**

Alterations of the antibody–receptor interactions can be induced by either alteration of the EGFR (82–92) or via competition with other EGFR ligands (87, 93–98).
EGFR Alterations
Several EGFR alterations have been reported in preclinical studies. First, loss of the EGFR phosphatase transmembrane protein tyrosine phosphatase RPTP sigma (PTPRS), which is known to directly interact, dephosphorylate, and inactivate EGFR (99), enhances EGFR-induced transformation and promotes EGFR/PI3K pathway activation, resulting in resistance to EGFR inhibition (88). Furthermore, constitutive activation of the EGFR, such as the EGFR variant III (EGFRvIII, activating mutation), results in activation of several downstream modulators (preferentially the PI3K pathway) and participates in increasing tumorigenicity and CTX resistance (92).

On the other hand, several CTX resistance mechanisms are based on the perturbation of CTX binding on EGFR. Indeed, contrary to the classic EGFR located on the plasma membrane, the nuclear EGFR (translocation mediated by the Src family kinases) cannot be targeted by CTX and, thus, functions as a transcription factor for several factors, inducing proliferation (cyclin D1, iNOS, B-myb, and aurora kinase A) (91). Moreover, the single nucleotide polymorphism encoding EGFRK521 (K-allele), which is expressed in >40% of HNSCC cases, has been shown to reduce stability of the EGFR and, thus, the affinity for CTX binding (85). Finally, the two concurrent, nonsynonymous missense G33S and N56K mutations in the extracellular domain of EGFR restrict adoption of a fully closed (tethered) and inactive EGFR conformation, thus, not permitting binding of CTX to the EGFR (82, 86).

Besides the preclinical evidence, clinical studies support some of the previously cited CTX-resistance mechanisms. Based on analysis of n=31 HNSCC (oral cavity) cases, Morris et al. find significant PTPRS loss or deletion in 32% of cases (88). They observed pathway activation (elevated levels of phospho-EGFR and phospho-AKT) in tumors with PTPRS deletion but not in tumors lacking PTPRS deletion. Smilek et al. show that a somatic EGFR mutation located in exon 19 may contribute to the limited clinical response to therapy with CTX plus radiotherapy (n=2/29 patients with advanced HNSCC) (86). Moreover, the high EGFRvIII expression, detected in 17%–42% of HNSCC tumors, was significantly and independently associated with shorter progression-free survival in patients with recurrent or metastatic HNSCC treated by CTX + Docetaxel (87, 92). For some authors, the role of this EGFR polymorphism in CTX resistance remains limited (100). The EGFR extracellular domain mutation G465R is reported to confer resistance to CTX by altering its binding to EGFR in a patient with a regional neck recurrence of an oral cavity HNSCC (83).

CTX-based combined therapy has been tested in the preclinical as well as clinical setting to overcome the previously
### TABLE 1 | Resistance mechanisms to chemotherapy (left), cetuximab (middle) and immunotherapy (right), described in head and neck squamous cell carcinoma.

| CHEMOTHERAPY | CETUXIMAB |
|--------------|------------|
| **Target alterations** | **DNA damage response effectors** ERCC1 expression, ATR, WE1 and PARP activation | **EGFR and its ligands** DNA damage response effectors ERCC1 expression, ATR, WE1 and PARP activation | **EGFR alterations** Loss of PTPRS, EGFR variant III, Nuclear translocation, SNP EGFR-K521, EGFR G465R and concurrent EGFR G33S and EGFR N56K | **EGFR downstream effectors** ATR, WEE1 and PARP activation | **Competition with other ligands** Aberrant expression of TGF-a, TGF-b, EGF, HB-EGF, amphiregulin and heregulin, STAT3 activation by EGFR, JAK2 or a Src Kinase, Src kinase activation, RAS/MAPK pathway activation, PI3K/Akt/mTOR pathway activation (e.g. PTEN mutation) |
| **Bypass pathway activation** | **Survivin expression** Increased XIAP and TRAIL expression | **RTK activation** MET, AXL, HER2, HER3, ROR2, IGF-1R and VEGFR | **Apoptosis evasion** Loss of the tumor suppressor gene TP53, Hypoxia (i.e. HIF-1α overexpression) | **Metabolism** | **Expression of lymphotakin** EGFR methylation, Secretion of CTX-containing extracellular vesicles, Upregulation of EMT-related genes, Loss of the tumor suppressor gene SMAD4 |
| **Epithelial-to-mesenchymal transition / cancer stem cells** | **NEDD4 overexpression** mIR-139-5p down-regulation, IL-6/STAT3 pathway activation, Increased expression of CD44 and Oct-4, Upregulation of ABC transporter genes, Increased ADH1 expression | **Epigenetic modifications** Activation of miR-302, Increased FOXD2-AS1 expression, Up-regulation of histone methyltransferase DOT1L, NFEL promoter hypermethylation, Elevated expression of PAK2, miR-629-3p expression | **Expression of growth factor receptors and EMT-related genes by:** DNA methylation, Histone modifications, Chromatin remodeling, Noncoding RNAs, Epigenetic modifications | **TME** | **Enhanced expression of miR-96-5p** ALK1 activation, SDF-1/ CXCR4 expression, Cancer associated fibroblasts (CAF) proliferation, Tregs and MDSC proliferation, T cells exhaustion or impairment, Toll-like receptor 4 (TLR4) pathway activation, Cancer associated fibroblasts (CAF) proliferation |
| **IMMUNOTHERAPY** | **Tumor Immunogenicity and Antigen presentation** Selection of subclones lacking the expression of neoantigens, downregulation of MHC class I (MHC-I), Loss of function of ϒ2-microglobulin, Alterations in STAT1 | **Oncogenic pathways** MAPK pathway, WNT/β-catenin pathway, PI3K pathway, Noncoding RNAs, Chromatin remodeling | **Soluble molecules** Secretion of pro-tumoral cytokines IL-6, and IL-10, IDO1 overexpression, Secretion of immunosuppressive exosomes containing TGF-β, PD-1 and CTLA4 | **Inhibitory checkpoint molecules** CTLA-4 expression in Treg TILs, LAG-3, TIM-3, KIR2DL-1, KIR2D-2, KIR2D-3, Noncoding RNAs, Chromatin remodeling | **Stimulatory agonist molecules** Costimulatory agonists: Ox40, 4-1BB, ICOS and CD40, Noncoding RNAs, Chromatin remodeling | **Immunosuppressive cells** Myeloid derived suppressor cells, Tregs, Tumor-associated macrophages |

For each resistance mechanism, preclinical and/or clinical evidence of their role in resistance as well as combined therapeutic strategies to overcome it are developed in the manuscript.
cited resistance mechanisms. Dasatinib (BMS-354825), a tyrosine kinase inhibitor (TKI), limits the nuclear EGFR translocation (by blocking the Src family kinases), which leads to increased EGFR on the plasma membrane and restores sensitivity to CTX (90). Thus, Dasatinib is currently evaluated in combination with CTX in patients with recurrent HNSCC (NCT01488318, phase 2) (84) as well as in combination with CTX/cisplatin/RT (NCT00882583, phase 1). Interestingly, in the CTX + Dasatinib combination setting, patients with low serum IL6 have shown clinical benefit and improved OS (NCT01488318) (84).

**Aberrant Expression of EGFR Ligands**

The CTX-EGFR interactions are reduced in the context of competitive interaction with the overexpression of some ligands, such as TGF-α, TGF-β, EGF, HB-EGF, amphiregulin, and the aberrant HER3 ligand heregulin-expression (87, 93–98). Thus, this autocrine/paracrine growth factor production reduces CTX effectiveness in several HNSCC cell lines.

Indeed, based on the analysis of tumor biopsies from n=47 recurrent/metastatic HNSCC, the amphiregulin overexpression (representing 47% of cases) was a statistically significant prognostic factor of worse OS and progression-free survival (87). Yonesaka et al. report that n=2/28 HNSCC tumor samples that presented aberrant heregulin expression comparable to that of HNSCC CTX-resistant cell lines (FaDuCR cells) were resistant to CTX (94).

Interestingly, FaDuCR recovered the sensitivity to CTX in combination with Pertuzumab (anti-HER2 antibody) (94). Indeed, Pertuzumab prevents the binding of HER2 with its ligand (heregulin), avoiding the coupling of HER2/HER3, thus, resulting in the absence of the HER3-AKT pathway activation, which is responsible for inducing CTX resistance.

**Alterations of EGFR Downstream Signaling Effectors**

Activation of downstream signaling effectors, such as STAT3 (signal transducer and activator of transcription 3) (77, 84, 101–106), Src Kinases (64, 107, 108), RAS/MAPK pathways (86, 96, 109–115), and PI3K/Akt/mTOR pathway (102, 105, 116–127) could induce CTX resistance independently of the EGFR-ligand activation.

**STAT3 Activation**

STAT3, a member of the STAT family of transcription factors, is considered as an oncogene activated in several cancers, including HNSCC (128). Its activation could be driven by EGFR as well as in an independent EGFR way by another growth factor receptor, the Janus kinase 2 (JAK2) or by the Src kinase family. Furthermore, loss of the PTPRS tumor suppressor gene that dephosphorylates STAT3 may lead to permanent activation of STAT3. Several studies report that hyperactivation of STAT3 is implicated in CTX treatment resistance.

Indeed, several HNSCC cell lines that develop acquired resistance to CTX are characterized by increased total STAT3 expression (77). The role of STAT3 in HNSCC cell CTX that acquires resistance is supported by recovering increased sensitivity to CTX (greater antiproliferative effects and cytotoxicity) when STAT3 is knocked down (104) or by blocking JAK2-STAT3 signaling (using miR-204) (101). Moreover, analysis of n=22 samples from patients with HNSCC tumors that recurred following CTX treatment finds increased phosphorylated STAT3 (103).

Regarding CTX-based combinations, guggulsterone, a natural compound contained in the Commiphora mukul plant resin used in Indian ayurvedic medicine and considered as an anti-STAT3 agent, enhances the efficacy of CTX when combined with CTX (106). Moreover, the combination of CTX + JAK2 inhibitor (miR-204) inhibits STAT3 activation, resulting in inhibition of angiogenesis and promotion of in vivo CTX sensitivity (101).

Given that STAT3 may be activated by the Src kinase family, Dasatinib (SRC inhibitor), which is tested in combination with CTX in phase-2 (84) and phase-1 clinical trials (NCT01488318 and NCT00882583, respectively), could provide some insight about the utility of the STAT3 inhibition in overcoming CTX resistance.

**Activation of Src Kinases**

Src family kinases are frequently overexpressed and/or activated in several cancers, including those arising in the head and neck (85). These nonreceptor protein tyrosine kinases play critical roles in signaling pathways, regulating cell division, motility, adhesion, angiogenesis, and survival (129). Thus, activation of Src kinases could be involved in proliferation/migration/invasion of cancer cells as well as in treatment resistance.

Based on gene expression profiles of CTX-resistant OSCC cells as well as of publicly available data sets, Uzawa et al. identified a 12-gene expression signature of CTX resistance, including the urokinase-type plasminogen activator receptor (uPAR) (107). They show that CTX resistance could be mediated by uPAR upregulation. Indeed, through the uPAR/integrin β1/Src/FAK signal circuit, the uPAR upregulation activates ERK1/2 phosphorylation to maintain cell proliferation/invasion resulting in CTX resistance in vitro and in vivo even in the absence of EGFR overexpression or acquired activating mutations. Src kinases could also induce CTX resistance by EGFR-ligand independent transactivation (cell-substratum adhesion), which phosphorylates ErbB3 to form a heterodimeric complex, inducing proliferation via AKT (108).

Based on previous evidence, the CTX-based combination with the Src inhibitor-1 or resveratrol (uPAR inhibitor) are shown to overcome CTX resistance in vitro and in vivo (tumor growth suppression and uPAR downstream protein downregulation), respectively.

**Activation of the RAS/MAPK Pathway**

The family of mitogen-activated protein kinases (MAPK) are a family of serin-threonin kinases implicated in the regulation of the majority of physiological cellular processes, including proliferation, differentiation, and apoptosis in response to changes in the cellular environment (130). In particular, the Ras/Raf/MEK/ERK1/2 (extracellular signal-regulated protein
kinases) cascade is the MAPK signaling cascade most frequently associated with carcinogenesis of several cancer types (131). Regarding HNSCC, this signaling cascade can be activated by several tyrosine kinase receptors, such as EGFR, as well as independently of them by alterations of the Ras/Raf oncogenes. This highlights the variety of CTX-resistance mechanisms involving this signaling cascade.

First, the MAPK signaling pathway activation related to the HNSCC CTX resistance could involve a RAS-activating mutation (G12V HRAS) (113). The restored sensitivity to CTX by silencing H-Ras in H-Ras mutant HNSCC cell lines reinforces this observation (132). However, activation of the RAS/MAPK pathway even in the absence of constitutive gene mutations could lead to CTX resistance (111). Indeed, overexpression of the K-Ras, H-Ras, and N-Ras proteins (96) leads to CTX resistance. Furthermore, dysregulation of the regulating proteins of the RAS/MAPK pathway could also contribute to CTX resistance as supported by the low expression of DUSP5 and DUSP6 (negative regulators of ERK1/2) and upregulation of AURKB (100) and AURKA (114), which are key regulators in mitosis.

In the clinical setting, Braig et al. show that acquisition of RAS mutant clones (KRAS G12S, G13C; NRAS Q61K, NRAS A146P; HHRAS G13R) correlates significantly with clinical resistance to CTX in a cohort of n=20 patients treated by CTX/platinum/5-fluorouracil treatment with monitoring of the circulating tumoral DNA (ctDNA) (110). The role of the KRAS p.Gly12Val mutation in CTX resistance previously found in vitro, is also demonstrated in only one patient carrying this mutation (among the n=29 studied) associated with an absence of response to treatment (86). Rampias et al. confirm that the HRAS mutation (n=7/50 patients with HNSCC) is associated with de novo resistance to CTX-based therapy (113). Overall, Bossi et al.’s observations (cohort of n=40 recurrent/metastatic HNSCC) are in accordance with others and show that overactivation of the RAS pathway leads to CTX/resistant cell survival (111).

On the basis of their results, especially the interesting observation of the crosstalk between the RAS/RAF/MAPK and PI3K/AKT pathways, Rampias et al. tested the combination of CTX + a PI3K inhibitor (LY294002) in an H-Ras mutated cell line and found a marked reduction of their viability (113). Apigenin, an ERK 1/2 inhibitor, in combination with CTX resulted in a significant decrease of HNSCC CTX-resistant cell survival (112). Interestingly, the combination of CTX + tipifarnib (farnesyltransferase inhibitor) showed enhancement of the tipifarnib antitumor effect through concomitant ERK inhibition in vitro and in vivo (109). Finally, a combination of CTX with inhibition of the ERK upregulators, i.e., aurora kinase knockdown (siRNA) and inhibitor (the pan aurora kinase inhibitor R763), showed inhibition of proliferation and increased apoptosis in HNSCC cell lines (112, 114, 115).

PI3K/Akt/mTOR Pathway

The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are involved in several physiological as well as pathological cellular processes, including proliferation, differentiation, survival, and motility (133). In HNSCC, PI3K/AKT/mTOR signaling is active in more than 90% of HNSCC as a result of EGFR activation, PI3K overexpression, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3KCA) mutations/amplifications, and PTEN mutation (116, 134). Activated PI3K/AKT/mTOR signaling is related to radiotherapy and cytostatic drug resistance, likely through enhanced DNA-repair mechanisms.

Several genetic alterations causing PI3K/AKT/mTOR activation, such as activating mutations in the oncogene PI3KCA or inactivating mutations in the tumor suppressor protein PTEN, are driving CTX resistance in different HNSCC cell lines (125, 127). Indeed, Izumi et al. show that loss of PTEN conferred independence from EGFR activity and resistance to EGFR inhibition by CTX in terms of downstream signaling, proliferation, and tumor growth both in vitro and in vivo xenograft models (119).

Moreover, Eze et al. recently reported the analysis of PTEN and PI3KCA expression in samples from patients with recurrent or metastatic HNSCC enrolled in two trials of cetuximab-based therapy (n=48 patients in the E5397 trial and n=37 in the NCI-8070 trial) (117). Patients with low PTEN expression had significantly worse survival.

Thus, CTX-based combined therapy has been realized using ATP-competitive PI3K inhibitors as well as mTOR inhibitors (Rapamycin and analogues). Regarding ATP-competitive PI3K inhibitors, the CTX combination with Buparlisib or BK1210 demonstrates the highest antiproliferative effect and inhibition of PI3K/protein kinase B, AKT/mTOR signaling pathways in vitro (122) and in vivo (121). The BYL719 (PI3Kz specific inhibitor), namely Alpelisib (123) and the Copanlisib (highly selective, pan-class I PI3K inhibitors) (120), are shown to improve CTX-induced tumor inhibition in HNSCC CTX-resistant cell lines and PDX. Interestingly, the combination of CTX plus the PK1-587 (PI3K/mTOR inhibitor), namely Gedeatosib, which restored sensitivity to CTX in resistant HNSCC cell lines and xenografts (124), is found to have a greater synergistic enhancement of the CTX effectiveness, especially in basal-like HNSCC cells with mutated CDKN2A (118). Regarding mTOR inhibitors, Rapamycin (RAD001) (126) and Temsirolimus (105) show improving CTX antiproliferative effects in xenografts.

Interestingly, combinations of CTX with PI3K/Akt/mTOR inhibitors are widely investigated in clinical trials. Regarding ATP-competitive PI3K inhibitors, there are several phase-1 and -2 trials enrolling patients with HNSCC to be treated by CTX + Buparlisib (BK120) (NCT01816984, phases 1 and 2), Alpelisib (BYL719) (NCT01602315, phases 1b and 2) (126), and Copanlisib (NCT02822482, phases 1b and 2, COPAN-ORL06, specifically for patients harboring a PI3KCA mutation/amplification and/or a PTEN loss). PX-866, a noncompetitive PI3K inhibitor, was also tested in combination with CTX (NCT01252628, phases 1 and 2). Analogues of the rapamycin, temsirolimus (NCT01256385, phase 2, MAESTRO HN) and everolimus (NCT01637194, phase 1; NCT01283334, phases 1 and 2) (57) have already brought some interesting results to overcome CTX resistance.
Bypass-Pathway Activation

Another resistance mechanism involves the abnormal activation of parallel signaling pathways to counteract the blockade of the EGFR signaling by CTX. Thus, cancer cell survival is ensured by increased expression/activation of alternative receptor tyrosine kinases (RTK) (50, 77, 79, 123, 135–150), ensuring the activation of several parallel pathways, including the VEGF pathway (72, 151–153).

Receptor Tyrosine Kinases

Among the growth-factor receptor family, RTK are transmembrane receptors implicated in several physiological as well as pathological (oncogenesis) processes (154). The binding ligand-extracellular domain induces receptor dimerization, activation of the intrinsic tyrosine-kinase activity of the RTK, and activation of downstream signaling cascades implicated in cell proliferation, differentiation, motility, survival, and cell–cell communication (155). Thus, activation of these RTKs is a mechanism of resistance to CTX during HNSCC treatment (50, 77, 79, 123, 135–150).

Indeed, the increased expression and activation of RTK, such as MET, AXL, HER2, HER3, and ROR2, are reported in several CTX-resistant cell lines (148) as well as in vivo (PDX). For example, MET/HGF (146) as well as AXL (123, 139, 148) overexpression and activation stimulate cell proliferation despite CTX treatment in vitro and in vivo, especially through MAPK downstream signaling. Recently, McDaniel et al. investigated the AXL-mediated CTX-resistance mechanisms in HNSCC and report that the tyrosine 821 of AXL mediates resistance to CTX by activation of c-ABL (oncoprotein) (156).

Other ErbB family members, ErbB2 (HER2) (102) and ErbB3 (HER3), could also be implicated in CTX resistance. Indeed, Yonesaka et al. report the persistence of ERK 1/2 signaling caused by the permanent activation of ErbB2 signaling (amplification of the receptor ErbB2 or upregulation of the ligand heregulin) induces CTX resistance in HNSCC cell lines (141). The restoration of CTX sensitivity through inhibition of ErbB2 or disruption of ErbB2/ErbB3 heterodimerization reinforce their observations. On the other hand, this heterodimerization also highlights the role of HER3 activation in resistance to CTX treatment of some HNSCC cell lines (135). The permanent activation of ErbB3/Akt signaling could be caused by an autocrine neuregulin expression (autocrine loop) as well as by aberrant HER3 ligand heregulin expression (94). Furthermore, increased activity of the IGF1R signaling pathways has been reported in several CTX-resistant HNSCC cell lines (136, 137, 143). IGF1R and HER3 activations with partial EGFR persistent activity are intertwined during CTX resistance as supported by the ability of a multitarget mAb mixture against EGFR, HER3, and IGF1R to overcome CTX resistance.

These preclinical observations are supported by clinical evidence. Indeed, in a retrospective cohort of n=57 patients with recurrent/metastatic HNSCC, patients who presented HGF/MET pathway overexpression and activation had worse prognoses (138). Moreover, Chung et al. report the case of a patient with recurrent HNSCC who presented an interesting response to AMG-479 (a monoclonal antibody against IGF-1R) after CTX resistance. Tumor sample analysis suggests the potential benefit of a combined therapy using AMG-479 plus CTX (142).

To overcome CTX-resistance, several combined therapies using RTK inhibitors have been tested. The BET inhibitor JQ1, which binds preferentially to the bromodomains of BRD4, abrogates the expression of the alternative RTK (HER3 and AXL), resulting in significantly delayed acquired resistance in two PDX models of HNSCC (148). Combined with CTX, MET inhibitor PHA-665752 is also shown to restore CTX sensitivity in vitro and in vivo, especially by decreasing akt and ERK1/2 phosphorylation (146, 147). Inhibition of the AXL receptor is explored by using imatinib (which targets c-Abl) in CTX-resistant HNSCC PDX (156). This led to complete tumor regression and a prolonged effect (no recurrence up to 3 months after cessation of treatment). Moreover, the Lida et al. experiment brings general support to the implication of several ErbB family members in CTX resistance. They find that the pan-HER mixture of six antibodies targeting EGFR, HER2, and HER3 decreases HER family receptors in acquired CTX-resistant HNSCC cells lines and overcomes CTX resistance in PDX (98). More precisely, a dual EGFR/HER2 inhibitor with CTX plus Afatinib shows significantly improved tumor volume reduction in CTX-resistant xenografts compared with either agent alone in monotherapy (140). ErbB3 inhibition has also been realized in vitro and in vivo using MM-121 (97, 113) as well as CDX-3379 (ErbB3-specific blocking antibody) (93). These combinations inhibit proliferation through inhibition of PI3K/Akt and ERK signaling pathways. When combined with CTX, the anti-IGF-IR antibody (IMC-A12) A12 provides important inhibitions of cell proliferation and migration in vitro and in vivo (regression of tongue cancer cell xenografts) (144). Although the rationale of dual VEGF and EGFR inhibition is proposed in several other cancers (157), Argiris et al. show that combined targeting of EGFR with CTX and VEGF with bevacizumab enhances growth inhibition both in vitro and in vivo (153).

Given that ErbB3 activation induced by heregulin is previously described as a CTX-resistance mechanism, the combination of Patritumab (U3-1287), an anti-HER3 monoclonal antibody, and CTX with platinum-based therapy was evaluated in a randomized, double-blind, phase-II study of first-line treatment of patients with recurrent or metastatic HNSCC (NCT02633800) (158). Although tolerable, the combination Patritumab + CTX + platinum was not superior to CTX + platinum. Based on the previous rationale as well as on a phase-I study (149), Deeken et al. evaluate the combination of lapatinib (which blocks both EGFR and ErbB2) plus CTX (NCT01184482) in patients with advanced solid malignant tumors, including HNSCC. Results were interesting with an overall response rate of 17% and a clinical benefit rate of 67%.

CDX-3379, an anti-ErbB3 monoclonal antibody, has been recently reported to inhibit tumor ErbB3 phosphorylation in HNSCC and induce measurable tumor regression and was well tolerated (93). Thus, a phase-2 clinical trial (NCT03254927) is ongoing and aims to determine the clinical benefit, safety, and
tolerability of combining CDX-3379 and CTX in patients with advanced HNSCC who have previously received CTX and progressed.

IGF-1R inhibitors are also widely explored in combination with CTX for recurrent/metastatic HNSCC. Glisson et al. as well as Ferrarotto et al. report no improvement of progression-free survival and OS using the Cixutumumab + CTX compared with CTX alone (159, 160). The OSI-906, a dual kinase inhibitor of both IGF-1R and insulin receptor was evaluated in combination with CTX among patients with HNSCC (NCT01427205, phase 2), but results are not available. More recently, the combination of CTX plus the anti-IGF-1R antibody A12 (IMC-A12) was evaluated in the neoadjuvant setting for patients with HNSCC NCT00957853 (Phase 2).

Finally, VEGF inhibitors combined with CTX have been also investigated. Although some results are not available (NCT00906360, phase 1, CTX + Sunitinib), others are contradictory. Indeed, although some trials report that bevacizumab + cisplatin + CTX + intensity-modulated radiation therapy (IMRT) in locally advanced HNSCC is associated with favorable efficacy outcomes (NCT00968435, phase 2), Argriris et al. find that adding bevacizumab increases toxicity without apparent improvement in efficacy (NCT00703976, phase 2) (151). Thus, the potential clinical benefit of combined EGFR–VEGF targeting is not clearly established.

Other Signal Transducers

Several proteins involved in classic cancer pathways, such as proliferation, apoptosis, invasion, and metastasis, could be altered and implicated in CTX resistance during HNSCC treatment (64, 115, 161–165).

Among all somatic genomic alterations in HNSCC, the tumor suppressor gene TP53 is the most frequent (166), highlighting its importance in carcinogenesis and progression. Indeed, although the tumor suppressor protein p53 has a critical role in cell cycle arrest, apoptosis, and senescence, loss of its function is linked to disease progression and treatment response (64). Regarding CTX, comparative analysis of sensitive vs. CTX-resistant HNSCC cells reveals the central role of the loss of p53 in the development of acquired resistance to CTX (163).

The precise role of hypoxia in acquired resistance to cetuximab is not clearly established, and further studies are needed. Indeed, Boeckx et al. find that the sensitivity to CTX is not altered but increased in HNSCC cells exposed to prolonged hypoxia (164). On the other hand, Lu et al. report that HNSCC cells with acquired CTX resistance express a high level of the alpha subunit of the hypoxia-inducible factor-1 (HIF-1α) and are highly glycolytic (aerobic glycolysis, i.e., the Warburg effect). Furthermore, the experimental overexpression of HIF-1α confers resistance to CTX as well as abolishes CTX-mediated radiosensitization in HNSCC cells (161).

These preclinical observations have caused Lu et al. to explore the inhibition of hypoxia and its relationship with CTX efficacy. Downregulation of HIF-1α by siRNA or a small molecule inhibitor (1-methyl 1, 9 PA) enhances response of CTX-resistant HNSCC cells to CTX plus radiotherapy (161). Finally, Lu et al. confirm that CTX inhibits HNSCC cell proliferation through inhibition of glycolysis and that the combination of CTX + oxamate (inhibition of LDH-A, an enzyme catalyzing the conversion of pyruvate to lactate in anaerobic conditions) improves the therapeutic effect of CTX in cancer cells (162). As a continuation of their work on the role of hypoxia and glycolysis during HNSCC treatment, Lu et al. explore the role in CTX resistance of the mitochondrial enzyme pyruvate dehydrogenase kinase-1 (PDH1), known to allow the switching of glucose metabolism toward aerobic glycolysis in cancer cells (165). They found that the combination of CTX plus PDK1 knockdown (siRNA) or with pharmacological inhibition of PDK1 with dichloroacetic acid (DCA) overcomes CTX-resistance in vitro and in vivo (xenografts) thanks to the overproduction of reactive oxygen species (ROS) and the subsequent apoptosis.

Epithelial-to-Mesenchymal Transition

The importance of EMT in human disease, especially in carcinogenesis, has been reviewed elsewhere (167). The EMT can be considered as a continuum of multiple and dynamic transitional states whereby cells exhibit epithelial, intermediate, and mesenchymal phenotypes. Regarding HNSCC, acquisition of an EMT phenotype (modulation of cell polarity and adhesion) by cancer cells is involved in disease progression as well as in CTX resistance (168–179).

Indeed, several authors report that HNSCC cells exhibiting a mesenchymal-like phenotype are resistant to CTX treatment in vitro and in vivo (xenografts) (174, 176, 177). Several potential mechanisms implicated in this EMT-induced CTX resistance are observed, such as (i) expression of lymphotoxin-b; (ii) methylation of EGFR that promotes the EGFR ligand-binding ability and dimerization (EGFR persistent activity) (169); (iii) secretion of CTX-containing extracellular vesicles, which lead to cancer cell protection (179); (iv) upregulation of EMRT-related genes (133), especially by epigenetic regulation (170, 180); and (v) loss of the tumor suppressor gene SMAD4, which induces JNK and MAPK pathway activation (172, 173). Indeed, Ozawa et al. find that SMAD4 loss is associated with CTX resistance and poor survival in HPV-negative patients (cohort of n=130 newly diagnosed and n=43 patients with recurrent HNSCC) (172). Thus, Ozawa et al. tested the combination of CTX + JNK inhibitor (SP600125) or MAPK/MEK inhibitor (U0126) and show that it contributes to overcome CTX resistance in vitro.

Moreover, the development of CTX resistance could also be accompanied by increasing hedgehog pathway transcription factor expression in vitro (175). Thus, Keysar et al. tested the combination of CTX and IPI-926 (hedgehog pathway inhibitor) in four different PDX models. This combination forced tumor cells into an EGFR-dependent state and blocked tumor recurrences.

Epigenetic Modifications

Epigenetic alterations, including DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs, are frequently involved in head and neck carcinogenesis, tumor progression, and resistance to therapy (137), especially to CTX (75).
As previously described, Kagohara et al. report that genes associated with CTX resistance in HNSCC cell lines, including TFAP2A, which regulates growth factor receptors and EMT, are epigenetically regulated (170). Stein-O’Brien et al. show that FGFR1 demethylation is associated with CTX resistance and this type of epigenetic alteration might stabilize the resistant phenotype (171). Interestingly, Shimizu et al. recently reported that nicotine (one of the main tobacco components) contributes to CTX resistance in vitro as well as in vivo (xenografts) (181). Indeed, they show that nicotine induces, through the nicotinic acetylcholine receptor, both EGFR phosphorylation and the subsequent Akt and mTOR downstream cascade activation and nuclear translocation of the phosphorylated EGFR.

Establishment of an Immunosuppressive TME
In addition to all the previously cited intrinsic resistance mechanisms, there are also extrinsic resistance mechanisms, i.e., involving the TME (182). These mechanisms encompass, in fact, the cancer cell–TME crosstalk, contributing to CTX resistance (40, 75). In HNSCC, establishment of an immunosuppressive microenvironment is an important resistance mechanism to treatment, especially to CTX (6, 70, 183, 184) (Figure 2).

Regulatory T Cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSC) Proliferation
Proliferation of immunosuppressive cells, such Tregs and MDSC, in response to CTX treatment is one of the key resistance mechanisms (185–188). Indeed, several coculture experiments show that CTX expands CTLA-4+FOXP3+ Tregs in part by inducing dendritic cell maturation. These Tregs lead to CTX resistance by suppressing the CTX-mediated ADCC (cytolytic functions of NK cells) (188). Based on the analysis of blood samples from CTX-treated patients with locally advanced/metastatic (stage III/IV) HNSCC (n=22 patients, NCT 00226239 and n=18, NCT 01218048), Jie et al. confirm their in vitro observations (188). Indeed, they find that CTX increased the frequency of intratumoral Tregs expressing the inhibitory checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is known to inhibit T cell activation (6). Thus, Tregs suppress the CTX-mediated ADCC. Their presence is correlated with poor clinical outcomes in these cohorts. Based on these results, Jie et al. tested CTX in combination with ipilimumab, a monoclonal antibody that also induces NK cell–mediated ADCC. Ipilimumab treatment enhanced the CTX-mediated ADCC by eliminating Tregs (targeting CTLA-4), allowing effector T cell activation and restoration of the cytolytic functions of NK cells (n=6 HNSCC tumors) (188).

Furthermore, Shayan et al. hypothesized that the combination of CTX plus motolimod, a small-molecule TLR8 agonist that can activate monocytes, DCs, and NK cells (189), might enhance T cell stimulation and CTX effects (187). They find that the TLR8 stimulation through motolimod skewed monocytes toward an antitumor M1 phenotype and reversed MDSC suppression of T cell proliferation. These in vitro observations are confirmed in patients. Indeed, in a phase-Ib trial (NCT02124850) enrolling n=14 patients with previously untreated stage-III/IV HNSCC, Shayan et al. tested the combination of CTX plus motolimod (formerly VTX-2337) (187). The combination reversed MDSC-induced immunosuppression and improved antitumor immunity with increased circulating tumor antigen-specific T cells (EGFR specific) and increased the number and function of tumor-infiltrating CD8 T cells. These encouraging results are confirmed in another phase-Ib study (n=13 patients with recurrent/metastatic HNSCC, NCT01334177) demonstrating the significant increasing antitumor activity of this combination (increased plasma cytokines and activated circulating NK cells). To finish, the potential benefit of adding motolimod to the standard EXTREME regimen (CTX + platinum + fluorouracil) was evaluated in a phase-2 trial enrolling n=195 patients with recurrent/metastatic HNSCC (NCT01836029) (185). Ferris et al. find that the combination fails to prove a benefit for survival when considering the intent-to-treat population, but significant benefits are observed when considering only the selected subgroup of patients with HPV-positive tumors and injection site reactions.

T Cell Exhaustion/Impairment
HNSCCs are among the most immune-infiltrated cancers, and several mechanisms are implemented by tumor cells to escape to the host immune defense system (190, 191). The immunomodulatory effect of CTX treatment, in particular ADCC, might be inhibited by cancer cells through several mechanisms inducing T cell exhaustion/impaired and all CTX resistance (67, 97, 192–194). Indeed, to counteract the antitumor activity of CTX, tumor cells express TGF-β, which inhibits the expression of cytotoxic effector molecules in immune cells (Apo2L/TRAIL, CD95L/FasL, granzyme B, and IFN-γ) and suppresses their ability to induce cetuximab-mediated ADCC (97).

Moreover, in a cohort of n=18 patients with stage-III/IV HNSCC treated by CTX alone (NCT 01218048), Jie et al. find that the increased frequency of PD-1+ and TIM-3+ tumor-infiltrating lymphocytes (TILs) during CTX treatment inversely correlates with objective response (200). Besides PD-1 and TIM immune checkpoint (ICP) receptors, KIR, the ICP on NK cells that modulate their activation, is also indirectly implicated in CTX resistance. Indeed, Faden et al. report a statistically significant increase of missense mutations and loss of heterozygosity in HLA-C (the ligand for KIR) in patients not responding to CTX compared with responders (196).

In accordance with the previously cited in vitro observations, several CTX combinations have been tested in the preclinical as well as clinic setting.

For example, Bedi et al. explored the combined effect of CTX and TGF-β blocking in vivo (PDX). Although CTX alone forced the selection of resistant clones, i.e., TGF-β-overexpressing tumor cells, the combined treatment prevented it and induced complete tumor regression (97). In the same way, Faden et al. observed increased HNSCC cell killing when combining CTX and lirilumab,
a monoclonal antibody that blocks NK inhibitory KIR signaling (196). Moreover, the upregulation of CD137 or 4-1BB (a member of the TNF-receptor superfamily, which is broadly induced and activated on several effective immune cells) was correlated to clinical response to neoadjuvant CTX (NCT01218048). Srivastava et al. tested the effect on several HNSCC cell lines of the combination CTX plus urelumab (BMS-663513, CD137-agonist monoclonal antibody) (201). This combination enhanced the CTX-mediated ADCC as supported by the increased NK-cell survival, DC maturation, and tumor antigen cross-presentation. Regarding other ICP inhibitory signals, Concha-Benavente et al. explored several HNSCC cell lines and found that the programmed death ligand-1 (PD-L1), which limits the function of activated T lymphocytes when they interact with the ICP receptor programmed death-1 (PD-1), is expressed by tumor cells in an EGFR- and JAK2/STAT1-dependent manner (159). Thus, they tested the combination of CTX and JAK2 inhibition. They found that JAK2 inhibition prevented tumor PD-L1 expression and that the combination enhanced the CTX NK-mediated killing via ADCC against PD-L1+ HNSCC cells.

The better comprehension of immune evasion mechanisms as well as of the immune-modulatory effect of CTX, i.e., CTX-mediated ADCC, brings evidence to support the evaluation of combined approaches with ICP inhibitors in both locally advanced and recurrent/metastatic HNSCC (6, 67, 192). Among the tested agents, inhibition of the PD-1/PD-L1 synapse is widely explored. The anti PD-1 Nivolumab, for which efficacy and safety prior to CTX in HNSCC has been recently reported (CheckMate 141) (205), is actually tested in combination with CTX in phase-1 and -2 trials for patients with recurrent/metastatic HNSCC (NCT03370276). Sacco et al. recently reported some preliminary results of the first trial evaluating the antitumor activity of anti-PD-1 Pembrolizumab combined with CTX in n=33 patients with platinum-refractory/ineligible, recurrent/metastatic HNSCC (NCT03082534, phase 2) (197). Results are promising with an observed 41% response rate. Regarding anti PD-L1, Durvalumab combined with CTX and radiotherapy is currently tested in a phase-I/II clinical trial (NCT03051906, DUCRO) (193). Based on previous safety studies (154, 163, 167), several clinical trials are testing the anti PD-L1 Avelumab in combination with CTX (NCT03494322, phase 2 EACH) (206) +/- radiotherapy (NCT02999087 phase 3 REACH) or Palbociclib (a selective CDK4/6 inhibitor) (NCT03498378 phase 1 and NCT02101034 phase 2) (195). Other interesting combinations involve the 4-1BB agonist Ureolumab (NCT02110082) (201), the anti-CTLA-4 monoclonal antibody ipilimumab (NCT01935921, phase 1) (202) and Monalizumab (anti NKG2A receptors expressed on TIL-CD8+ and NK cells) (NCT02643550) (199).

FIGURE 2 | Molecular mechanisms contributing to Cetuximab resistance through the establishment of an immunosuppressive TME. Red lines and arrows show mechanisms contributing to Cetuximab resistance, and green lines and arrows show mechanisms contributing to Cetuximab sensitivity. (EGFR, Epidermal Growth Factor Receptor; NK, Natural Killer; PD1, Programmed death 1; PDL1, Programmed Death Ligand 1; KIR, Killer Immunoglobulin-like Receptor; ADCC, Antibody-dependent cellular cytotoxicity; HLA-C, Human leukocyte antigen-C; TGF, transforming growth factor; Treg, regulatory T-cells; MDSC, Myeloid-derived suppressor cells).
Toll-Like Receptor 4 (TLR4) Pathway Activation

TLR4 is an innate immune receptor involved in defense against microbial agents by recognizing inflammation-associated microbial ligands (such as lipopolysaccharide) and promoting the activity of innate immune cells (207). TLR4 are also expressed by tumor cells, and the role of the TLR4 signaling pathway in the TME has been reviewed elsewhere (208). Unfortunately, by inducing immunosuppressive cytokines, apoptosis resistance, and EMT, the TLR4 signaling pathway can promote cancer cells’ immune escape in several cancer types (including lung, pancreas, and ovarian cancers, HNSCC) as well as resistance to therapy (paclitaxel in ovarian cancer) (209–212).

Indeed, Ju et al. recently reported that the crosstalk between the EGFR and TLR4 pathways could participate in CTX resistance in vitro and in vivo (xenograft) (213). They found that EGFR inhibition led to decreased MyD88 degradation, and thus, MyD88 could activate TLR4 (receptor homodimerization). TLR4 activation induced activation of NF-κB and MAPK signaling pathways, resulting in the release of proinflammatory cytokines (TNF-α, iNOS, COX2, PGE2, NO) favoring EGFR permanent activation as well as the release of anti-apoptosis proteins (Bcl-2, Bcl-xl) allowing tumor cell survival. Overall, the TLR4 signaling pathway leads to CTX-resistance. Thus, Ju et al. tested the combination of CTX and a TLR4 inhibitor (TAK242). They find that this combination overcomes acquired CTX resistance in vivo, in particular by decreasing the secretion of pro-inflammatory cytokines (TNF-α, PGE2, and NO) (175).

CAF Proliferation

Among the different components of the HNSCC TME, CAFs are among the most critical elements contributing to proliferation, invasion, and metastasis (214), in particular by altering the antitumor immune response (215, 216). Furthermore, CAFs have been shown to contribute to drug resistance in HNSCC (e.g., platinum and CTX) (42, 217–219).

Indeed, during CTX treatment, CAFs, especially those activated by TGF-β (218), participate in resistance by secreting immunosuppressive factors, such as IL-6, HGF, and metalloproteinases (219). Thus, co-inhibition of TGF-β and HNSCC cells by the combination of CTX + SIS3 (an inhibitor of the TGF-β pathway), delayed tumor progression and lowered tumor volume/weight (HNSCC PDX) (218). Johansson et al. also tested the combined effect of CTX + MMP inhibitor III (inhibiting MMP-1, -2, -3, -7, and -13), which significantly reduced the protective effect of CAFs (219).

IMMUNOTHERAPY IN HNSCC

HNSCC is among the most inflamed, immune-infiltrated cancers, especially with CD8+ TILs and NK cells (183). A high genetic instability and somatic mutation rate is often observed (220, 221) (about 180 somatic mutations per mega base), in either HPV positive or negative tumors (222, 223). Immunogenicity of HNSCC can result from the overexpressed but nonmutated native proteins that have escaped central tolerance, neo-antigens derived from mutated proteins (224), or HPV-induced viral antigens (e.g., oncopgenic drivers E6 and E7) (225). The microenvironment can also vary in terms of intensity or constitution depending on carcinogens or localization (226).

Genetic and epigenetic alterations in cancer cells create a vast array of neoepitopes potentially recognizable by the immune system. However, a key feature of malignant cells is their ability to escape recognition by the immune system, and the dysregulation of immune checkpoints, such as PD-L1, in tumors appears to be a major immune-resistance mechanism affecting T cell response. It was, hence, shown that the reversal of the anergic state of T lymphocytes is possible via the blockade of coinhibitory signals (227), and research initially focused mainly on immune checkpoint inhibitors (ICI) of the PD-L1/PD-1 axis. These antibodies (Abs) have since completely transformed the treatment of R/M HNSCC.

The expression of PD-L1 is positive in most cases, estimated at almost 60%–70% with a higher expression in HPV+ compared to HPV- tumors (228, 229). It results either from an immune-adaptive phenomenon induced by IFNγ or from intrinsic oncogenic events, such as the mutation/deletion of the PTEN suppressor gene or the deregulation of the AKT/mTOR, NF-kB and mitogen-activated protein kinase (MAPK) pathways (230). PD-1 binding with PD-L1/PD-L2 causes immunosuppression via reduced T cell receptor (TCR) signaling, reduced cytokine production, reduced target cell lysis, altered lymphocyte motility, and metabolic reprogramming (231).

After showing antitumor activity in multiple other tumor types, nivolumab was the first anti-PD-1 agent to improve OS in recurrent/metastatic (R/M) HNSCC progressing after a first-line platinum-based therapy in the Checkmate 141 trial with a 32% reduction in the risk of death (205, 232). OS was 7.7 months compared with 5.1 months with chemotherapy. Benefit was greater in ≥1% PD-L1 positive (PD-L1+) TPS (tumor cell membrane positivity for PD-L1 or tumor proportion score) patients with an OS of 8.2 versus 4.7 months. Pembrolizumab is the other agent to show efficacy in the second line in the Keynote-040 trial (233). Median OS was 8.4 vs 6.9 months with a hazard ratio (HR) of 0.80. Contrary to the Checkmate 141 essay, crossover was allowed. Subgroup analysis shows that, for PD-L1 TPS ≥50% patients, survival was significantly increased from 7.9 to 11.6 months with immunotherapy, whereas there was no difference for the PD-L1<50% population.

This same agent is the new standard of front-line therapy in R/M HNSCC following the results of the Keynote-048 trial comparing pembrolizumab alone or in combination with platinum-based and 5FU chemotherapies to the EXTREME standard of care protocol (cisplatin or carboplatin, 5-fluorouracile (5FU) and cetuximab) (234). Survival was significantly increased with pembrolizumab compared with the EXTREME regimen for PD-L1 ≥20 CPS (expression on both tumor cells and immune cells in the microenvironment or combined positive score) patients (14.7 vs. 11 months) and PD-L1 ≥1 CPS patients (12.3 vs. 10.4 months) but not in the total population (11.5 vs. 10.7 months). It is important to note
that the experimental treatment was deleterious for some patients in the beginning with more deaths occurring in the first 6 months. Pembrolizumab added to chemotherapy significantly improved OS in the total population with safety comparable to the EXTREME arm (13 vs. 10.7 months). The median duration of response was impressive with pembrolizumab at 22.6 months (vs. 4.5 for EXTREME). Tolerance was also far better with immunotherapy. The FDA approved pembrolizumab for use in combination with platinum and fluorouracil for all patients and as a single agent for patients with a CPS ≥1. In Europe, the EMA approved the use of pembrolizumab alone or in combination for patients with a CPS ≥1. Unlike PD-L1, blockade of cytotoxic T-lymphocyte antigen 4 (CTLA4) as monotherapy has not proven beneficial in HNSCC.

Evidently, monotherapy with ICI seems to be a losing battle despite providing substantial clinical improvements over the previous standards of care. The majority of patients do not respond to treatment, and durable responses are observed only in a minority (generally less than one third) of patients.

**Resistance to Immune Checkpoint Inhibitors**

Resistance to ICI can be primary (never-responder patients) or secondary (acquired after a certain amount of time of response). It can also be classified as intrinsic to tumor cells (cancer cells directly induce immune resistance via various mechanisms) or extrinsic (other cells or factors mediate immune resistance).

HNSCC hijacks numerous cellular and molecular immunomodulatory pathways to evade recognition and eradication by the immune system. Mechanisms of immune evasion include direct T cell suppression with surface or soluble inhibitory factors, decreased immune stimulation, and the recruitment of immuno-suppressive cell populations (231). In this section, we review the different types of resistance reported in HNSCC and present some of the currently studied strategies to overcome them.

**Intrinsic Resistance**

**Tumor Immunogenicity and Antigen Presentation**

HNSCC is one of the cancers with the highest levels of tumor mutational burden (TMB), accompanying elevated neoantigen expression (220). These tumoral neoantigens that derive from nonsynonymous mutations drive (T lymphocytes) TL cytotoxic response against tumor cells. In that sense, a positive correlation between response and TMB was found in a recent meta-analysis (235). Constant interactions between immune and cancer cells can result in a selection of subclones lacking the expression of neoantigens, subsequently resulting in poor immunogenicity and decreasing efficacy of ICI (236). This could explain how some HNSCC tumors with high TMB are unresponsive to ICI.

Furthermore, deficiencies in antigen presentation can result in primary or acquired resistance to ICI as shown in multiple studies (237, 238). This includes downregulation of MHC class I (MHC-I) and loss of function (e.g., truncating mutations) of β2-microglobulin (238). HNSCC has been shown to alter neoantigen presentation and processing by altering key genes, such as signal transducer and activator of signal (STAT) 1 and other antigen processing machinery components (239, 240).

Combining ICI with radiation therapy is a promising strategy as radiotherapy leads to an increased rate of neoantigens and antigen presentation induced by DC activation, increased cytokine production, and tumor cell death, promoting a TIL phenotype (241, 242). Chemotherapy increases antigen release upon cell death and, thus, the priming of cytotoxic TL (243), and this was the rational in combining platinum-based chemotherapy with ICI in the Keynote-048 trial that resulted in added benefit (234).

Emerging novel therapies include oncolytic virus therapy and cancer vaccines with tumor peptides or DCs (244, 245). Their aim is to enhance antigen presentation and TL priming. Oncolytic viruses can also directly infect and induce lysis of tumor cells. Talmogene laherparepvec (TVEC), which is derived from herpes simplex virus type 1, is currently under evaluation in combination with pembrolizumab in the Keynote-137 trial in R/M HNSCC patients. Other novel therapeutics, such as toll-like receptor (TLR) agonists (NCT02521870) and adoptive cell therapy (NCT03247309), are also being evaluated in this same context.

**Oncogenic Pathways**

Aberrations in canonical oncogenic pathways can change the TME by altering cytokine production and immune cell composition. These include the MAPK (246), WNT/β-catenin (247), and PI3K pathways (248). The activation of the latter creates an immunosuppressive TME. Combined inhibition of PD-1 and PI3K in a preclinical model of HNSCC demonstrates a synergistic growth inhibitory effect and increased survival of mice by activating an immunostimulatory transcriptional program, enhancing T cell cytotoxicity and expression of proinflammatory cytokines (249).

**Soluble Molecules**

HNSCC cells can also avoid T cell rejection by secreting immunosuppressive exosomes containing transforming growth factor (TGF) β, PD-1, and CTLA4, which impair T and NK cell functions and upregulate Tregs (250). They can also produce and secrete promutual cytokines, including TGF-β, interleukin (IL)-6, and IL-10 (251). Tumor cells can overexpress Indoleamine 2,3-dioxygenase 1 (IDO1), a rate-limiting enzyme that converts tryptophan to kynurenine, leading to an immune suppression through T cell apoptosis and loss of function. In a study of the immune microenvironment of HPV-negative OSCC from never-smoker and never-drinker (NSND) patients, it was suggested that blockade of IDO1 and PD-1/PD-L1 could insure a higher clinical benefit. However, a phase-III clinical trial evaluating Epcadostat, an IDO inhibitor, in combination with Pembrolizumab was halted after a similar trial in melanoma revealed no improvement compared with the control arm (252).
Extrinsic Resistance Inhibitory Checkpoint Molecules

Overexpression of alternative immune checkpoints can be a source of adaptive resistance to ICI. These receptors serve to limit effector functions of the immune system to prevent autoimmunity in a normal state. Multiple inhibitory immune checkpoint receptors with different cell distributions and expression patterns have been described, including PD-L1, CTLA4, lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin, mucin domain-3 protein (TIM-3), B and T lymphocyte attenuator (BTLA), V-domain immunoglobulin-containing suppressor of T cell activation (VISTA), and T cell immunoreceptor tyrosine-based inhibition motif domain (TIGIT) (253, 254).

PD-L1 status has been shown to be partially correlated with response to ICI in HNSCC, but complete responses have been observed in PD-L1-negative patients (232–234). CTLA4 is upregulated in HNSCC tumor cells and enriched on Treg TILs (255). These cells are a subset of CD4+ T cells with immunosuppressive effects through various humoral and cellular mechanisms, such as CTLA4-mediated suppression of antigen-presenting cells (256). LAG-3 is expressed on activated CD4+ and CD8+ T cells, NK cells, B cells, and DCs (257). It binds with major histocompatibility complex class II (MHCII) and is highly expressed on Tregs. It was shown that blockade of LAG-3 decreases the inhibitory function of these cells (257). TIM-3 is expressed on both T and NK cells and binds with galectin-9 (258). When specifically coexpressed with PD-1, TIM-3 is the signature of an exhausted T cell phenotype (259).

Because these alternate coinhibitory receptors induce T-cell exhaustion (231), they have been identified as a putative strategy to overcome resistance to PD-1 in previous and many ongoing studies. Based on these observations, two essays of ICI anti-PD1 and anti-CTLA4 combination in HNSCC have been reported to date (260). The CONDOR trial compared outcomes of patients who had low/ negative PD-L1 (TPS<25%) tumors and had progressed after first-line platinum-containing therapy. Patients were treated with either durvalumab, an anti-PDL1 Ab, or tremelimumab, an anti-CTLA4 Ab, or the combination (260). Results were deceiving as there was no significant increase in response rate (RR) (7.8% vs. 9.2%), PFS (2 vs. 1.9 months) or OS (7.6 vs. 6 months) compared with durvalumab alone. One toxic death from acute respiratory failure was attributed to the combination regimen. The same combination failed to improve survival regardless of PD-L1 status in the EAGLE trial (261). Monotherapy with the anti-CTLA4 agent in CONDOR appeared clearly ineffective with a 1.6% RR, a 1.9 and 5.5 median PFS and OS, respectively (260). The authors hypothesize that the lack of efficacy of tremelimumab may be in part related to its mechanism of action, which, as an IgG2 Ab, does not cause lysis of regulatory T cells through ADCC, contrary to what is observed with ipilimumab, another anti-CTLA4 agent (262).

Inhibitors of other checkpoint molecules, such as TIM-3 and LAG-3, are still in earlier phases of development. For example, blockade of TIM-3, whose expression is synonymous to T cell exhaustion, is efficient in producing an antitumoral T cell response in a mouse model of HNSCC (263).

Inhibitory checkpoints can also be expressed on the surface of innate immune cells, such as NK cells. The inhibitory killer immunoglobulin-like receptor (KIR) 2DL-1, -2, -3 receptors, which partially control NK cell activation upon binding with their ligands, primarily human leukocyte antigen-C (HLA-C) molecules, can be targeted by Lirilumab, a fully human IgG4 monoclonal Ab. PD-1 blocking on T cells can induce the release of cytokines, such as IL-2, that enhance NK cell function, whereas blockade of KIR can result in the secretion of IFN-γ that may boost T cell–mediated antitumor responses (264). This rationale of NK–T cell crosstalk led to the testing of the combination in phase-1/2 trials (265).

Stimulatory Agonist Molecules

The balance between co-inhibitory and costimulatory signals is what determines the state of the immune response. Costimulatory agonists include Ox40, 4-1BB, inducible T cell co-stimulator (ICOS), and CD40. Ox40 is expressed on the surface of T cells and promotes proliferation and IFN-γ production. It is shown to be present in HNSCC, but expression of its ligand (Ox40L) is reduced, rendering this pathway ineffective (266). ICOS is expressed on the same cells, promoting a Th2 response [62], and 4-1BB, present on the surface of activated T cells, NK cells, and DCs, is shown to be downregulated in HNSCC patients (267).

Many promising ongoing trials are evaluating receptor agonists in order to reverse resistance to ICI and augment durable responses. For example, agonists of ICOS are being evaluated in combination with anti-PD-1, anti-CTLA-4, and chemotherapy in various tumors, including HNSCC (NCT03693612, NCT02904226). In addition, urelumab (an agonistic 4-1BB monoclonal antibody), is evaluated in combination with cetuximab (NCT02110082) in R/M HNSCC patients.

Immunosuppressive Cells

In addition to all the complex interactions between co-inhibitory and costimulatory pathways, immunosuppressive cells can modulate the immune response and create a protumoral environment via multiple diverse mechanisms (268). Their recruitment to the TME is regulated by HNSCC cells. MDSCs, Tregs, and TAMs all modulate NK and T cell responses to various degrees.

MDSCs are an immature myeloid cell population that promotes HNSCC invasiveness, angiogenesis, and metastasis (269, 270) by secreting immunosuppressive enzymes, such as enzymes arginase 1 (Arg-1) and nitric oxide synthase (iNOS) (251). Their presence correlates with poor outcomes with ICI as shown in melanoma patients (271). Monoclonal Ab and small molecule inhibitors that inhibit MDC functions are currently investigated in R/M HNSCC patients in various clinical trials.

Tregs facilitate self-tolerance through direct contact and inhibitory cytokines, such as IL-10 and TGF-β (272), they also
play a key role in immune evasion in HNSCC. These cells preferentially express CCR4 (believed to have a major role in the recruitment of Tregs to the TME), which is being targeted with an anti-CCR4 monoclonal antibody, mogamulizumab, in different tumor types, including HNSCC.

TAMs, particularly M2 macrophages, enhance tumor angiogenesis, motility, growth, and immune evasion by secreting protumoral cytokines in the TME [69]. Their presence in HNSCC is associated with poor prognosis (273). Antibodies and small molecules that inhibit colony-stimulatory factor 1 receptor (CSF1R) binding with CSF1, which serves recruitment to the tumor of M2 TAMs, are currently underway in various advanced solid tumors, including HNSCC (NCT02526017).

CONCLUSIONS AND PERSPECTIVES

Treatment of the majority of patients with HNSCC requires multimodality approaches. Currently, cetuximab is used in the clinical routine as a radiation sensitizer alone or in combination with chemotherapy for the treatment of patients with recurrent or metastatic disease. More recently, pembrolizumab was approved as a first-line therapy in patients who present with metastatic disease, and treatment with either pembrolizumab or nivolumab is used in the setting of cisplatin-refractory recurrent or metastatic HNSCC. Despite the encouraging results observed in some patients, tumor responses observed in most patients are only partial and are systematically followed by acquired resistance due to reactivation of oncogenic signaling, leading to tumor regrowth, as discussed in this review.

Most of the developments toward understanding HNSCC have fallen short of clinically meaningful discoveries, highlighting an urgent need for more effective therapies to improve treatment outcomes. The increasing knowledge on the genomic driver alterations in HNSCC enables their use as predictive markers of targeted therapy regimens, currently evaluated in clinical trials, which are shown to improve survival and tumor response in subgroups of patients (274, 275). For instance, late-phase clinical trials show that HRAS-mutant HNSCC patients (8% of HNSCC) treated with tipifarnib, a selective farnesyltransferase inhibitor, shows promising outcomes with an overall response rate (ORR) of 42.9% with a median duration of response of 14.7 months (275). The Akt/mTOR axis is activated in most HNSCC, particularly in surrounding normal mucosa, and is associated with recurrences. In this context, a phase-II trial (NCT01111058) shows significant improvement in 1-year PFS in patients with locally advanced HNSCC treated with everolimus (276). More recently, Xevinapant, an investigational inhibitor of apoptosis protein (IAP) blocker, showed prolonged OS when added to standard chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Based on these results, Xevinapant received breakthrough therapy status from the FDA for the first-line treatment of HNSCC in September 2020.

The molecular heterogeneity of HNSCC has hampered the identification of specific targets and, thus, the development of targeted therapies for this group of tumors (51). Indeed, much of the difficulty in studying and treating HNSCC lies in the fact that they are a heterogeneous group of cancers arising from distinct anatomic subsites that display distinct molecular features and are associated with diverse risk factors. However, these diseases are treated uniformly and with limited success.

Genome-wide expression profiling led to the identification of four robust molecular classes of HNSCC (277–279). In this classification, the “classical,” “basal,” and “mesenchymal” subtypes exhibit canonical genomic alterations, such as nuclear factor erythroid 2–related factor 2 (NFE2L2) mutations and high expression of genes in oxidative stress response pathways, high frequency of HRAS mutations, and upregulation of EMT-related genes, respectively (278, 279). Of note, multiple findings have led to increased interest in the mechanisms by which cancer cells undergoing EMT or oscillating within the EMT spectrum might contribute to immune escape through various routes. The “atypical” subtype contains a high proportion of HPV+ tumors, which themselves are very heterogeneous and can be subclassified into HPV-KRT (HPV-keratinocyte differentiation and oxidative reduction process) or HPV-IMU (HPV-immune response and mesenchymal cell differentiation) tumors (69). These different subtypes of HNSCC may harbor different patterns of sensitivity to oncogenic-driven targeted therapy and radiotherapy (280, 281); however, the clinical implication of these subtypes is currently unknown.

More recently, based on the gene expression profiles of 1368 patients with SCC in the Cancer Genome Atlas (TCGA), Li B et al. (282) proposed six immune subtypes, including an immune-cold subtype, an immune-hot subtype, a subtype dominated by M2-polarized macrophages, and three other immune subtypes with more diverse immunologic features. Their association with response or resistance to immunotherapy is unclear.

Complementary strategies to assess the molecular programs that are specific to each histological subtype or anatomical location of HNSCC may benefit from comprehensive analyses of patient samples (283) to identify molecular vulnerabilities and, thus, enable rapid clinical deployment to guide therapeutic decisions. Furthermore, single-cell transcriptomics may help revealing intratumoral heterogeneity (ITH) (284, 285) with subtypes as well as identifying cell populations that drive drug resistance. Spatial transcriptomics might also be an informative approach to enable simultaneous capture of the distribution and localization of the different components of the TME and, thus, better understand its interaction in response to treatment. Finally, the establishment of relevant preclinical models of HNSCC (ref) that reflect the disease at the genetic, histological, and functional level may provide a tool to study the molecular modifiers of response to therapies currently used in the clinical routine or tested in clinical trials.

Overall, understanding the molecular vulnerabilities of HNSCC may contribute to identify and therapeutically target...
residual disease and prevent or delay the evolution of acquired resistance. Of note, acknowledging that drug resistance depends not only upon cancer cells but also upon the TME might enable the identification of potential drug targets to limit cancer cell adaptation to therapy.

**AUTHOR CONTRIBUTIONS**

SO-C, JB, AK, JF, and PS: contributed to this paper with the design. SO-C, JB, AK, JF, and PS: drafting. SO-C, JB, AK, JF, and PS: revision and editing. SO-C, JB, AK, JF, and PS: final approval. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by funding from the Integrated Cancer Research Site LYriCAN (INCa-DGOS-Inserm_12563). SO-C received funding from the Fondation ARC pour la Recherche sur le Cancer (ARCPJA20202060002212). JB received funding from Nuovo Soldati Foundation (2019) and ITMO Cancer 2020, Formation à la Recherche Fondamentale et Translationnelle en Cancérologie.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* (2018) 68:394–424. doi: 10.3322/caac.21492
2. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin Oncol Off J Am Soc Clin Oncol [Internet] (2015) 33:3235–42. doi: 10.1200/JCO.2015.61.6995
3. Young D, Xiao CC, Murphy B, Moore M, Fakhry C, Day TA. Increase in head and neck cancer in younger patients due to human papillomavirus (HPV). *Oral Oncol* (2015) 51:27–30. doi: 10.1016/joraloncology.2015.03.015
4. Karabjakin A, Toussaint P, Neidhardt E-M, Paulus V, Saintigny P, Fayette J. Chemotherapy for recurrent/metastatic head and neck cancers. *Anticancer Drugs* (2017) 28:357–61. doi: 10.1097/CAD.0000000000000473
5. Caramel J, Ligier M, Puisieux A. Pleiotropic roles for ZEB1 in cancer. *Carcinogenesis* (2008) 29:1057–85. doi: 10.1093/carcin/bgn073
6. Starzewska A, Wolter M, Glodek A, Karpuk M, Banasik A, Berezowska D, et al. miR-338 regulates epithelial-mesenchymal transition and ROS production in head and neck cancer cells. *J Cell Physiol* (2016) 231:3685–93. doi: 10.1002/jcp.25226
7. Einsele H, von Kalle C. Prognostic and predictive factors in head and neck cancer. *Oncology* (2015) 87:401–9. doi: 10.1159/000381401
8. Steinbichler TB, Metzler V, Pritz C, Riechelmann H, Dudas J. Tumor-associated microRNAs: implications for head and neck cancer. *Oral Oncol* (2015) 51:27–30. doi: 10.1016/joraloncology.2015.03.015
9. Shao Q, Zhang P, Ma Y, Lu Z, Meng J, Li H, et al. MicroRNA-139-5p affects the epithelial-to-mesenchymal transition. *Cell Cycle* (2015) 14:3369–75. doi: 10.1080/15352402.2015.1038508
neck cancer in a window of opportunity trial. *Clin Cancer Res* (2019) 25:1156–64. doi: 10.1158/1078-0432.CCR-18-2024

27. Gupta A, Ajith A, Singh S, Panday RK, Samayia A, Shukla S. PAK2-c-Myc- PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect. *Cell Death Dis* (2018) 9:1–15. doi: 10.1038/s41419-018-0887-0

28. Chikuda J, Otsuka K, Shimomura I, Ito K, Miyazaki H, Takahashi RU, et al. CD44S induces MiR-629-3p expression in association with cisplatin resistance in head and neck cancer cells. *Cancers (Basel)* (2020) 12:856. doi: 10.3390/cancers12040856.

29. Vahabi M, Pulito C, Sacconi A, Donzelli S, D’Andrea M, Manciocco V, et al. MiR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. *J Exp Clin Cancer Res* (2019) 38:141. doi: 10.1186/s13046-019-1119-x

30. Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, Yang CZ, et al. Xiap is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. *PloS One* (2012) 7:e31601. doi: 10.1371/journal.pone.0031601

31. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, et al. The Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. *Clin Cancer Res* (2009) 15:1645–54. doi: 10.1158/1078-0432.CCR-08-2581

32. Kumar B, Yadav A, Lang JC, Cipolla MJ, Schmitt AC, Arradaza N, et al. The PKM2 axis plays an essential role in head and neck oncogenesis via cytoplasmic survivin levels. *Mol Cancer Ther* (2012) 11:1988–98. doi: 10.1158/1535-7163.MCT-11-0674

33. Knauer SK, Unruhe B, Karczewski S, Hecht R, Fetz V, Bier C, et al. The tumor stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma. *APMIS* (2015) 123:205–14. doi: 10.1111/apm.12344

34. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. *J Biol Chem* (1962) 237:1555–62. doi: 10.1016/S0021-9289(19)3739-0

35. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). *Dev Biol* (1965) 12:394–407. doi: 10.1016/0012-1606(65)90005-9

36. Hung L, Sun Y, de la Pompa JL, Li H, Alroy J, Todaro GJ, et al. Herbit RS. Review of epidermal growth factor receptor biology. *Int J Radiat Oncol Biol Phys* (2004) 59:21–10. doi: 10.1016/j.ijrobp.2003.11.041

37. Bertotti A, Sassi F. Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. *Clin Cancer Res* (2015) 21:3377–83. doi: 10.1158/1078-0432.CCR-14-0848

38. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers (Basel)* (2019) 7:9–52. doi: 10.3390/cancers9050052

39. Baro M, Lopez Sambrooks C, Burtenshaw LB, Lemonn MA, Contessa JN, Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. *Mol Cancer Ther* (2019) 18:2124–34. doi: 10.1158/1535-7163.MCT-19-0163

40. Alsahafi E, Begg K, Amelio I, Raufi N, Lucarelli P, Sauter T, et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. *Cell Death Dis* (2019) 10:1–17. doi: 10.1038/s41419-019-1769-9

41. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGF-R in cancer. *Mol Oncol* (2018) 12:3–20. doi: 10.1002/1878-0261.12155. doi: 10.1002/isosc.180261.reviews

42. Solomon LW, Frustino JL, Loree TR, Brecher ML, Alberico RA, Sullivan M. Ewing sarcoma of the mandibular condyle: Multidisciplinary management optimizes outcome. *Head Neck* (2008) 30:405–10. doi: 10.1002/hed.20922.abstract

43. Ang KK, Berkey BA, Tu X, Zhang H-Z, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck cancer. *Cancer Res* (2002) 62:7350–6.

44. Rubin Grands J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. *J Natl Cancer Inst* (1998) 90:759–764. doi: 10.1093/jnci/90.11.759

45. Goupi S, Moreau Bachelard C, Kamal M, Gan HK, Borcoman E, Torossian N, et al. Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. *JNCI Cancer Spects* (2019) 3:plk055. doi: 10.1093/jncics/plk055

46. Sturgeon K, Digiovanni L, Good J, Salvatore D, Fenderson D, Domchek S, et al. Exercise-Induced Dose-Response Alterations in Adipopecton and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer. *Cancer Epidemiol Biomarkers Prev* (2016) 25:1193–200. doi: 10.1158/1055-9966.EPI-15-1087

47. Sacco AG, Worden FP. Molecularly targeted therapy for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). *Oral Oncol* (2013) 49:835–41. doi: 10.1016/j.oraloncology.2013.04.010

48. Brands RC, De Donno F, Knierim ML, Steinacker V, Hartmann S, Seher A, et al. Muti-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro. *Oncol Lett* (2019) 18:2220–31. doi: 10.3892/ol.2019.10541

49. Limaye S, Riley S, Zhao S, O’Neill A, Posner M, Adkins D, et al. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCLC). *Oral Oncol* (2013) 49:835–41. doi: 10.1016/j.oraloncology.2013.04.010

50. Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. *J Cancer* (2013) 4:86–83. doi: 10.7150/jca.5122

51. Wheeler SE, Shi H, Lin F, Dasari S, Bednash J, Thorne S, et al. Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models. *Head Neck* (2014) 36:385–92. doi: 10.1002/hed.23312

52. Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and INGS5. *Genome Biol* (2019) 20:12. doi: 10.1186/s13059-018-1604-0

53. Zhang D, Ding L, Li Y, Ren J, Shi G, Wang Y, et al. Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. *Sci Rep* (2017) 7:16231. doi: 10.1038/s41598-017-1341-y

54. Matsuoka Y, Yoshida R, Nakayama H, Nagata M, Hirose A, Tanaka T, et al. The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma. *APMIS* (2015) 123:205–14. doi: 10.1111/apm.12344

55. rho}
monoclonal antibody triggers tumor antigen-specific T cell immunity. *Immunol Res* (2011) 50:248–54. doi: 10.1007/s12026-011-8231-0

63. Khoranizer SC, Deramo N, Vivesca D, Varumou C, Strida G, Fortunato M, et al. Elevation of basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy. *Cancer Immunol Immunother* (2017) 66:573–9. doi: 10.1007/s00262-017-1960-8

64. Bocck C, Baay M, Wouters A, Speecenier P, Vermorken JB, Peeters M, et al. Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. *Oncologist* (2013) 18:850–64. doi: 10.1634/theoncologist.2013-0112

65. Schmitz S, Ang KK, Vermorken J, Haddad R, Suarez C, Wolf GT, et al. Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. *Cancer Treat Rev* (2014) 40:390–404. doi: 10.1016/j.ctrv.2013.09.007

66. Bonner JA, Azarnia N, Jones CU, Jassem J, Baselgia J, Rovinsky EK. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* (2006) 12:567–78. doi: 10.1056/NEJMoa053422

67. Taberna M, Oliva M, Mesiti C, Groves MW, Byrd JK, et al. The molecular landscape of head and neck cancers. *Clin Cancer Res* (2019) 25:2171.

68. Azoury SC, Gilmore RC, Shukla V. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC). *Discovery Med* (2016) 21:507–16.

69. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancers. *Nature* (2015) 517:576–82. doi: 10.1038/nature14129

70. Lawrence MS, Sougnez C, Lichtenstein L, Cibulskis K, Lander E, Gabriel SB, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* (2015) 517:576–82. doi: 10.1038/nature14129

71. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment. *Clin Cancer Res* (2011) 17:5197–204. doi: 10.1158/1078-0432.CCR-10-3338

72. Smilek P, Neuwirthova J, Jarkovsky J, Dusek L, Rottenberg J, Kostrica R, et al. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. *Neoplasia* (2012) 59:506–15. doi: 10.4149/neop_2012_06

73. Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapy of head and neck cancer. *Front Oncol* (2019) 9:383. doi: 10.3389/fonc.2019.00383

74. Tinhofer I, Klinghammer K, Weichert W, Knödler M, Stenzinger A, Gauler T, et al. Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment. *Clin Cancer Res* (2011) 17:5197–204. doi: 10.1158/1078-0432.CCR-10-3338

75. Morris LGT, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. *Proc Natl Acad Sci U.S.A.* (2011) 108:19024–9. doi: 10.1073/pnas.1111963108

76. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors—impact on future treatment strategies. *Nat Rev Clin Oncol* (2010) 7:493–507. doi: 10.1038/nrclinonc.2010.97

77. Li C, Iida M, Dunn EF, Wheeler DL. Dassatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. *Radiother Oncol* (2010) 97:330–7. doi: 10.1016/j.radonc.2010.06.010

78. Li C, Iida M, Dunn EF, Gha J, Wheeler DL. Nuclear EGFR Contributes to Acquired Resistance to Cetuximab. *Oncogene* (2009) 28:3801–13. doi: 10.1038/onc.2009.234

79. Sok JC, Coppelli FM, Thomas SM, Lange MN, Xi S, Hunt JL, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. *Clin Cancer Res Off J Am Assoc Cancer Res* (2006) 12:5064–73. doi: 10.1158/1078-0432.CCR-06-0913

80. Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, et al. Molecular and Clinical Activity of CDX-3379, an Anti-EGFR Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. *Clin Cancer Res Off J Am Assoc Cancer Res* (2019) 25:5752–8. doi: 10.1158/1078-0432.CCR-18-3453

81. Yonesaka K, Tanaka K, Kitano M, Kawakami H, Hayashi H, Takoda M, et al. Ablanterr HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. *Oncogenesis* (2019) 8:54. doi: 10.1371/journal.pone.0229077

82. Allender A, Jeddins A, Johansson A-C, Roberk B. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells. *J Oral Pathol Med* (2016) 45:9–16. doi: 10.1111/jop.12310

83. Saki M, Toulany M, Rodemann HP. Acquired resistance to cetuximab is mediated by EGFR-K521 polymorphism. *Cancer Res* (2017) 77:1188–99. doi: 10.1158/0008-5472.CAN-16-0754

84. Stabile LP, Egloff AM, Gibson MK, Gooiding WE, Ohr J, Zhou P, et al. Jib6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlations in cetuximab-resistant head and neck cancer. *Oral Oncol* (2017) 69:38–45. doi: 10.1016/j.oraloncology.2017.03.011

85. Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapy of head and neck cancer. *Front Oncol* (2019) 9:383. doi: 10.3389/fonc.2019.00383
131. Leeelahavanchikul K, Amornphimoltham P, Molinolo AA, Basile JR, Koontongkaew S, Gutkind JS. A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. *Mol Oncol* (2014) 8:105–18. doi: 10.1016/j.molonc.2013.10.003

132. Rampias T, Giagini A, Matsuzaki H, Bartzi V, Siolos S, Vaja E, et al. Genetic alterations in HRAS gene in relation to outcome and response to cetuximab in head and neck squamous cell carcinoma. *J Clin Oncol* (2012) 30:5574. doi: 10.1001/jco.2012.30.15_suppl.5574

133. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. *Front Oncol* (2014) 4:64. doi: 10.3389/fonc.2014.00064

134. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman C, Luthar N, et al. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. *Clin Cancer Res* (2016) 22(8):2013–20. doi: 10.1158/1078-0432.CCR-15-2853

135. Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, Amin ARMR, et al. Resistance to Therapy in Head and Neck Cancers. *Cancer* (2011) 1078-0432.CCR-16-0558

136. Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, et al. Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. *Mol Cancer Ther* (2016) 15:2175–86. doi: 10.1158/1535-7163.MCT-16-0112

137. Kijewski E, Lindstedt T, Fröhlich C, Olsen JV, Horak ID, Kragh M, et al. Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures. *Mol Cancer Ther* (2016) 15:1614–26. doi: 10.1158/1535-7163.MCT-15-0565

138. Madoz-Gurpide J, Zazo S, Charnizo C, Casado V, Caramés G, Gavín E, et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. *J Transl Med* (2015) 13:282. doi: 10.1186/s12976-015-0633-7

139. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman C, Luthar N, et al. AXL mediates resistance to cetuximab therapy. *Cancer Res* (2014) 74:5152–64. doi: 10.1158/0008-5472.CAN-14-0294

140. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. *Clin Cancer Res* (2011) 17:5935–44. doi: 10.1158/1078-0432.CCR-11-0370

141. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Elferink LA, Resto VA. Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer. *J Signal Transduct* (2011) 2011:1–11. doi: 10.1155/2011/992878

142. McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, et al. AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. *Clin Cancer Res* (2020) 26:4349–59. doi: 10.1158/1078-0432.CCR-19-3142

143. Brand TM, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, et al. AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. *Clin Cancer Res* (2020) 26:4349–59. doi: 10.1158/1078-0432.CCR-19-3142

144. Brand TM, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, et al. AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. *Clin Cancer Res* (2020) 26:4349–59. doi: 10.1158/1078-0432.CCR-19-3142

145. Forster MD, Dillon MT, Kocsis J, Remena et al. Potential for mAb Mixtures. *Mol Cancer Ther* (2016) 15:1614–26. doi: 10.1158/1535-7163.MCT-15-0565

146. Madoz-Gurpide J, Zazo S, Charnizo C, Casado V, Caramés G, Gavín E, et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. *J Transl Med* (2015) 13:282. doi: 10.1186/s12976-015-0633-7

147. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman C, Luthar N, et al. AXL mediates resistance to cetuximab therapy. *Cancer Res* (2014) 74:5152–64. doi: 10.1158/0008-5472.CAN-14-0294

148. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. *Clin Cancer Res* (2011) 17:5935–44. doi: 10.1158/1078-0432.CCR-11-0370
181. Shimizu R, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Resistance. J Cell Biochem. (2016) 117:2682–92. doi: 10.1002/jcb.25592
182. Nief MA, Huang RY-J, Jackson RA, Thyri JP, Abell AN, Jordan NV, et al. EMF. 2016. Cell (2016) 166:216–25. doi: 10.1016/j.cell.2016.06.028
183. Smith A, Teknos TN, Pan Q. Epithelial to Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. Oral Oncol (2013) 49:287–92. doi: 10.1016/j.oraloncology.2012.10.009
184. Hsu DS-S, Hwang W-L, Yeh C-H, Chu C-H, Ho Y-H, Chen P-B, et al. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck cancer cells. Cancers (2019) 117:2682–92. doi: 10.3390/cancers110708929
185. Fujiwara T, Eguchi T, Sogawa C, Ono K, Murakami J, Ibaragi S, et al. Anti-EGFR Fc Receptor. Front Pharmacol (2017) 8:339. doi: 10.3389/fphar.2017.00332
186. Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, et al. Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Cancer Res (2017) 77:2788–92. doi: 10.1158/1078-0432.CCR-16-1440
187. Boeckx C, Blockx L, de Beeck KO, Limame R, Van Camp G, Peeters M, et al. Establishment and characterization of cetuximab resistant head and neck cancer cells. Clin Cancer Res (2018) 24:62–72. doi: 10.1158/1078-0432.CCR-17-0357
188. Stephenson RM, Lim CM, Matthews M, Dietzch G, Hershberg R, Ferris RL, et al. Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. Mol Cancer Ther (2019) 18:1190–9. doi: 10.1158/1054-3597.MCT-19-0214
189. Brien G, Kagohara LT, Li S, Thakar M, Ranaweera R, Ozawa H, et al. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res (2018) 24:62–72. doi: 10.1158/1078-0432.CCR-17-0357
190. Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, et al. Interleukin-27 in the Tumor Microenvironment. J Cell Biochem (2016) 117:2682–92. doi: 10.1002/jcb.25592
191. La Fleur L, Johansson A-C, Roberg K. A CD44high/EGFRlow Subpopulation of Tumor Cells Enhances Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. Cancer Biol Ther (2015) 16:2504–11. doi: 10.4161/cbr.36561
192. Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig AJ, et al. SMAD4 and SMAD7 Levels Correlate with Cetuximab Response and Induction of MAPK Activation in Head and Neck Cancer Cells. Clin Cancer Res (2017) 23:5162–75. doi: 10.1158/1078-0432.CCR-16-1686
193. Cheng H, Fertig EJ, Ozawa H, Hatakeyama H, Howard JD, Perez J, et al. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol Ther (2015) 16:2515–24. doi: 10.1080/10535472.2015.1056418
194. Keyser SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, et al. Evidence for mesenchymal-like subpopulations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene (2010) 29:1470–82. doi: 10.1038/onc.2010.170
195. Holz C, Niehr F, Boyko M, Hristovska T, Distel L, Budach V, et al. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiother Oncol (2012) 101:158–64. doi: 10.1016/j.radonc.2011.05.042
196. Basso D, Nguyen T-T, TK, Montone KT, Zhang G, Wang L-P, Diehl JA, et al. Evidence for mesenchymal-like subpopulations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene (2010) 29:1470–82. doi: 10.1038/onc.2010.170
197. Boccardi C, Blockx L, de Beeck KO, Limame R, Van Camp G, Peeters M, et al. Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. Am J Cancer Res (2015) 5:1921–38. doi: 2156-6976/ajcr0008298
198. Fujisawa T, Fuzi T, Sugawa C, Ono K, Murakami J, Ibaragi S, et al. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGFR-driven mesenchymal transition. Biochem Biophys Res Commun (2018) 503:1267–72. doi: 10.1016/j.bbrc.2018.07.035
199. Kogohara LT, Zamuner F, Considine M, Allen J, Yegnasubramanian S, Gaykalova DA, et al. Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with cetuximab resistance in HNSCC sensitive cell lines. bioRxiv (2019), 729384. doi: 10.1101/729384
200. Shimizu R, Ibaragi S, Eguchi T, Kuwajima D, Kodama S, Nishiohka T, et al. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma. Int J Oncol (2019) 54:283–94. doi: 10.3892/ijol.2019.9892
201. Trédan O, Galmairini CM, Patel K, Tannock IF. Drug Resistance and the Solid Tumor Microenvironment. JNCI J Natl Cancer Inst (2007) 99:1441–54. doi: 10.1093/jnci/djm135
202. Mandal R, Şenbubaoğlu Y, Desrichard A, Havel JD, Dalog M, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight (2016) 1:e9928. doi: 10.1172/jci.insight.e9928
203. Concha-Benavente F, Ferris RL. Reversing EGFR Mediated Immunosuppression by Targeted Monoclonal Antibody Therapy. Front Pharmacol (2017) 8:339. doi: 10.3389/fphar.2017.00332
204. Ferris RL, Saba NF, Gillitiz BJ, Haddad R, Sukari A, Neupane P, et al. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Activ8 Randomized Clinical Trial. JAMA Oncol (2018) 4:1583–8. doi: 10.1001/jamaoncol.2018.1888
avetumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. *Radiother Oncol* (2020) 142:79–84. doi: 10.1016/j.radonc.2019.08.007

199. Fayette J, Lefebvre G, Posner MR, Bauman J, Salas S, Even C, et al. Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCCHN). *Ann Oncol Off J Eur Soc Med Oncol* (2018) 29 (Suppl 8):vi7–4. doi: 10.1093/annonc/mdy287.005

200. Iie H-B, Srivastava RM, Agris G, Bauman JE, Kane LP, Ferris RL. Increased Frontiers in Oncology | www.frontiersin.org February 2021 | Volume 11 | Article 614332

201. Ziani L, Choubai S, Thierry J. Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. *Front Immunol* (2018) 9:414. doi: 10.3389/fimmu.2018.00414

202. Takahashi H, Sakakura K, Kawabata-Iwakawa R, Rokudai S, Toyoda M, Nishiyama M, et al. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma. *Cancer Immunol Immunother* (2015) 64:1407–17. doi: 10.1007/s00262-015-1742-0

203. Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala R. Cross Talk between Toll-Like Receptor Pathways in Macrophages and Dendritic Cells. *Front Immunol* (2018) 9:414. doi: 10.3389/fimmu.2018.00414

204. Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, et al. A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Nivolumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). *Ann Oncol* (2016) 27:571. doi: 10.1093/annonc/mdw353.31

205. Ferris RL, Blumenschein GJ, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Phase I trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* (2016) 375:1856–67. doi: 10.1056/NEJMoa1602252

206. Forster MD, Sacco JJ, Kong AH, Wheeler G, Forsyth S, Bhat R, et al. EACH: A Randomised phase II study evaluating the safety and anti-tumour activity of the combination of avetumab and cetuximab relative to avelumab mono-therapy in recurrent/metastatic head and neck squamous cell cancer. *J Clin Oncol* (2019) 37:TPS6091–TPS6091. doi: 10.1200/JCO.2019.37.15_suppl.TPS6091

207. Hirsch I, Janovec V, Stranska R, Bendriss-Vermare N. Cross Talk between Inhibitory Immune Receptor Tyrosine-Based Activation Motif-Signaling and Toll-Like Receptor Pathways in Macrophages and Dendritic Cells. *Front Immunol* (2017) 8:32. doi: 10.3389/fimmu.2017.00394

208. Li J, Yang F, Wei F, Ren X. The role of toll-like receptor 4 in tumor microenvironment. *Oncotarget* (2017) 8:66656–67. doi: 10.18632/oncotarget.19105

209. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes tumor escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. *Mol Immunol* (2007) 44:2850–9. doi: 10.1016/j.molimm.2007.01.022

210. Szajnik M, Szczepanski MJ, Czstowska M, Glinka B, Grus K, Glinka B, et al. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. *Cancer Res* (2016) 76:1031–43. doi: 10.1158/0008-5472.CCR-16-0879

211. Ferris RL, Clump DA, Ohr J, Gooding W, Kim S, et al. Each: A phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCCHN). *Ann Oncol Off J Eur Soc Med Oncol* (2018) 29 (Suppl 8):vi7–4. doi: 10.1093/annonc/mdy287.005

212. Bauman J, Ferris RL, Clump DA, Ohr J, Gooding W, Kim S, et al. Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). *Ann Oncol* (2016) 27:571. doi: 10.1093/annonc/mdw353.31

213. Ju H, Hu Z, Lu Y, Wu Y, Zhang L, Wei D, et al. TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma. *Am J Cancer Res* (2020) 10:454–72. doi: 2156-6976/ajcr0104647

214. Curry JM, Sprando J, Cognetti D, Lugnubihl A, Bar-ad V, Pribitkin E, et al. Tumor microenvironment in head and neck squamous cell carcinoma. *Lancet Oncol* (2014) 14:217–34. doi: 10.1016/s1470-2045(14)70036-0
245. Guo ZS, Liu Z, Bartlett DL. Oncolytic Immunotherapy: Dying the Right Frontiers in Oncology | www.frontiersin.org February 2021 | Volume 11 | Article 614332

247. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 17:9–26. doi:10.1016/j.devcel.2009.06.016

240. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates [TAP1]-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother (2015) 64:525–35. doi:10.1007/s00262-016-1967-7

243. Ruiz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun (2016) 7:10501. doi:10.1038/ncomms10501

242. Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy for Cancer Treatment: Current Understanding. Oncogene 2017;36:1210421

246. Checchi EW, Soulieres D, Le Tournecq C, Buis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London England) (2019) 393:159–67. doi:10.1016/S0140-6736(18)31999-8

241. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London England) (2019) 394:1915–28. doi:10.1016/S0140-6736(19)31570-1

247. Ortì P, Huz, Keski DB, Shukla SA, Sun J, Böyum DJ, et al. Immunogenic personal neoantigen vaccine for patients with melanoma. Mol Oncol (2017) 11:1239005. doi:10.1016/j.molonc.2017.11.006

246. Checchi EW, Soulieres D, Le Tournecq C, Buis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London England) (2019) 393:159–67. doi:10.1016/S0140-6736(18)31999-8

241. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London England) (2019) 394:1915–28. doi:10.1016/S0140-6736(19)31570-1

247. Ortì P, Huz, Keski DB, Shukla SA, Sun J, Böyum DJ, et al. Immunogenic personal neoantigen vaccine for patients with melanoma. Mol Oncol (2017) 11:1239005. doi:10.1016/j.molonc.2017.11.006

246. Checchi EW, Soulieres D, Le Tournecq C, Buis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London England) (2019) 393:159–67. doi:10.1016/S0140-6736(18)31999-8

241. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London England) (2019) 394:1915–28. doi:10.1016/S0140-6736(19)31570-1

247. Ortì P, Huz, Keski DB, Shukla SA, Sun J, Böyum DJ, et al. Immunogenic personal neoantigen vaccine for patients with melanoma. Mol Oncol (2017) 11:1239005. doi:10.1016/j.molonc.2017.11.006
characterise [T] cells from head and neck cancer patients. *Immunobiology* (2012) 217:669–75. doi: 10.1016/j.imbio.2011.11.005

268. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol* (2013) 14:1014–22. doi: 10.1038/ni.2703

269. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of [CD34]{}(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. *Clin Cancer Res Off J Am Assoc Cancer Res* (1995) 1:95–103.

270. Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. *Immunol Cell Biol* (2013) 91:493–502. doi: 10.1038/icb.2013.29

271. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of circulating [MDSC] correlate with clinical outcome of melanoma patients treated with ipilimumab. *Cancer Immunol Immunother CII* (2014) 63:247–57. doi: 10.1007/s00262-013-1508-5

272. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. *Immunity* (2014) 41:49–61. doi: 10.1016/j.immuni.2014.06.010

273. Costa NL, Valadares MC, Souza PPC, Mendonça EF, Oliveira JC, Silva TA, et al. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. *Oral Oncol* (2013) 49:216–23. doi: 10.1016/j.oraloncology.2012.09.012

274. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. *Sci Transl Med* (2013) 5:196ra99. doi: 10.1126/scitranslmed.3005747

275. Walter V, Yin X, Winkler MD, Cabanski CR, Zhao N, Du Y, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. *PloS One* (2013) 8:e56823. doi: 10.1371/journal.pone.0056823

276. Ho AL, Hanna GJ, Scholz CR, Gualberto A, Park SH. Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations. *J Clin Oncol Am Soc Clin Oncol (ASCO)* (2020) 38:6504–4. doi: 10.1200/JCO.2020.38.15_suppl.6504

277. Nathan CAO, Hayes DN, Harismendy O, Flores J, Moore-Medlin T, Gutkind JS, et al. Multi-Institutional Randomized Double-Blind Phase II Trial of Everolimus vs. Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN). *Int J Radiat Oncol Biol Phys* (2020) 106:1116. doi: 10.1016/j.ijrobp.2019.11.392

278. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. *Cancer Cell* (2004) 5:489–500. doi: 10.1016/S1535-6108(04)00112-6

279. Network C.G.A. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* (2015) 517:576–82. doi: 10.1038/nature14129

280. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Daidone MG, Bossi P, Locati L, et al. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. *Oncotarget* (2015) 6:9627–42. doi: 10.18632/oncotarget.3301

281. Fox J-P, Bazire L, Ortiz-Cuaran S, Deneuve S, Kielbassa J, Thomas E, et al. A 13-gene expression-based radiosensitivity score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. *BMCCancer Med* (2017) 15:165. doi: 10.1186/s12916-017-0929-y

282. Li B, Cui Y, Nambiar DK, Sunwoo JB, Li R. The Immune Subtypes and Landscape of Squamous Cell Carcinoma. *Clin Cancer Res* (2019) 25:3528–37. doi: 10.1158/1078-0432.CCR-18-4085

283. Ferrarotto R, Mitani Y, McGrafl D, Li K, Karpinets TV, Bell D, et al. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. *Clin Cancer Res* (2020). doi: 10.1158/1078-0432.CCR-20-1192. clincanres.1192.2020.

284. Puram SV, Tirosi I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. *Cell* (2017) 171:1611–24.e24. doi: 10.1016/j.cell.2017.10.044

285. Tirosi I, Izar B, Prakash MD, Wadsworth MH, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science (80-)* (2016) 352:189–96. doi: 10.1126/science.aad0501

Conflict of Interest: PS receives research grants from HTG Molecular Diagnostics, Inviva, Bristol-Myers Squibb, Roche Molecular Diagnostics, Roche, AstraZeneca, Novartis, Bristol-Myers Squibb Foundation, and Illumina. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Ortiz-Cuaran, Bouaoud, Karabajakian, Fayette and Saintigny. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.